[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 513
1. Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood; 2009 Jan 22;113(4):775-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
  • Differentiation syndrome (DS) can be a life-threatening complication in patients with acute promyelocytic leukemia (APL) undergoing induction therapy with all-trans retinoic acid (ATRA).
  • We present an analysis of the incidence, characteristics, prognostic factors, and outcome of 739 APL patients treated with ATRA plus idarubicin in 2 consecutive trials (Programa Español de Tratamientos en Hematología [PETHEMA] LPA96 and LPA99).
  • [MeSH-major] Anthracyclines / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Risk Factors. Syndrome. Time Factors


2. Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P, European APL Group: Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood; 2010 Mar 4;115(9):1690-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
  • Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term results of this treatment, when CT should be added to ATRA and the role of maintenance treatment, remain uncertain.
  • In our APL93 trial that included 576 newly diagnosed APL patients, with a median follow-up of 10 years, 10-year survival was 77%.
  • The 10-year cumulative incidence of deaths in complete response (CR), resulting mainly from myelosuppression, was 5.7%, 15.4%, and 21.7% in patients younger than 55, 55 to 65, and older than 65 years, respectively, supporting the need for less myelosuppressive treatments, particularly for consolidation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adult. Aged. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Europe. Female. Follow-Up Studies. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20018913.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00599937
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


3. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood; 2006 Apr 1;107(7):2627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
  • Arsenic trioxide, as a single agent, has proven efficacy in inducing molecular remission in patients with acute promyelocytic leukemia (APL).
  • There is limited long-term outcome data with single-agent As2O3 in the management of newly diagnosed cases of APL.
  • Between January 1998 to December 2004, 72 newly diagnosed cases of APL were treated with a regimen of single-agent As2O3 at our center.
  • Single-agent As2O3, as used in this series, in the management of newly diagnosed cases of APL, is associated with responses comparable with conventional chemotherapy regimens.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Partial Thromboplastin Time. Platelet Count. Remission Induction. Survival Analysis. Treatment Outcome


Advertisement
4. Barón MA, Khamashta MA, Hughes GR, D'Cruz DP: Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis; 2005 Jan;64(1):144-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the prevalence of abnormal ankle-brachial indexes (ABIs), their relationship with other cardiovascular risk factors and/or the presence of antiphospholipid antibodies (aPL), and the clinical use of the ABI in patients with primary antiphospholipid syndrome (primary APS).
  • No correlation between abnormal ABI and traditional cardiovascular risk factors nor with the presence of aPL was found.
  • [MeSH-minor] Adult. Arteriosclerosis / diagnosis. Arteriosclerosis / etiology. Blood Pressure. Cardiovascular Diseases / etiology. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608314.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1755181
  •  go-up   go-down


5. Mrózek K, Bloomfield CD: Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr; 2008;(39):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
  • Acquired genetic alterations such as balanced and unbalanced chromosome aberrations and submicroscopic gene mutations and changes in gene expression strongly affect pretreatment features and prognosis of adults with acute myeloid leukemia (AML).
  • The most frequent chromosome/molecular rearrangements, that is, t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 characteristic of core-binding factor (CBF) AML and t(15;17)(q22;q12-21)/PML-RARA characteristic of acute promyelocytic leukemia (APL), confer favorable clinical outcome when patients receive optimal treatment, that is, regimens that include high-dose cytarabine for CBF AML and all-trans-retinoic acid and/or arsenic trioxide for APL.
  • Recently, mutations in such genes as KIT in CBF AML and FLT3 in APL have been correlated with clinical features and/or outcome of patients with these AML subtypes, and microarray gene expression profiling has been successfully used for diagnostic purposes and to provide biologic insights.
  • These data underscore the value of genetic testing for common translocations for diagnosis, prognostication, and, increasingly, selecting therapy in acute leukemia.
  • [MeSH-major] Chromosomes, Human / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Inversion. Core Binding Factors / genetics. Humans

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648004.001).
  • [ISSN] 1052-6773
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factors
  •  go-up   go-down


6. Rubenwolf P, Lopau K, Gerharz EW, Heidbreder E, Riedmiller H: [Antiphospholipid antibody syndrome: a priori a contraindication to kidney transplantation?]. Aktuelle Urol; 2007 Mar;38(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A general APL antibody screening prior to kidney transplantation does not seem to be justified at present.
  • [MeSH-minor] Adult. Graft Survival. Heparin / administration & dosage. Heparin / therapeutic use. Humans. Injections, Intravenous. Injections, Subcutaneous. Intraoperative Care. Lupus Erythematosus, Systemic / blood. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / diagnosis. Partial Thromboplastin Time. Risk Factors. Warfarin / administration & dosage. Warfarin / therapeutic use


7. Mishra MN, Rohatgi S: Antiphospholipid antibodies in young Indian patients with stroke. J Postgrad Med; 2009 Jul-Sep;55(3):161-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Stroke may be caused by antiphospholipid antibodies (APL), especially in young persons without other risk factors.
  • AIM: The aim of this study was to determine the prevalence of two clinically significant APL-anticardiolipin antibody (ACL) and lupus anticoagulants (LA) in young patients presenting with sudden neurological deficit.
  • APL (LA and ACL) were present in 29.4% of the samples and in 4% of controls.
  • CONCLUSIONS: APL, positive family history and smoking were significantly associated with stroke in the young.
  • We advocate screening for APL in all young patients with stroke.
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Smoking / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Postgrad Med. 2010 Jan-Mar;56(1):49; author reply 49-50 [20393258.001]
  • (PMID = 19884738.001).
  • [ISSN] 0972-2823
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Biomarkers
  •  go-up   go-down


8. De Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, Zini G, Pagano L, Sica S, Leone G: The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost; 2005 Sep;3(9):1985-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
  • BACKGROUND: Thromboembolism can occur during acute leukemia, especially acute lymphoid leukemia (ALL) treated with L-asparaginase.
  • Yet, most reports are anecdotical and scarce data are available on the risk of thrombosis in acute myeloid leukemia (AML).
  • OBJECTIVES: To evaluate the risk of thrombosis in patients with acute leukemia.
  • PATIENTS AND METHODS: Three-hundred and seventy-nine consecutive adult patients with newly diagnosed acute leukemia were recruited in an observational cohort study conducted from January 1994 to December 2003.
  • Diagnosis was ALL in 69 patients, acute promyelocytic leukemia (APL; FAB subtype M3) in 31, and non-M3 AML in 279.
  • At diagnosis, thrombosis was a presenting manifestation in 13 cases (3.4% of the whole cohort): 1.4% in ALL, 9.6% in APL, and 3.2% in non-M3 AML patients.
  • At 6 months from diagnosis, the cumulative incidence of thrombosis was 10.6% in ALL, 8.4% in APL, and 1.7% in non-M3 AML patients.
  • CONCLUSIONS: In patients with acute leukemia, the risk of thrombosis is not negligible.
  • Thombosis can be a presenting symptom at diagnosis in a significant portion of cases with APL (9.6%) and non-M3 AML (3.2%); a similar rate of thrombosis can occur during the subsequent course of the disease.
  • [MeSH-major] Leukemia / complications. Thrombosis / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Asparaginase / adverse effects. Female. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Incidence. Male. Middle Aged. Risk

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102104.001).
  • [ISSN] 1538-7933
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


9. Shen HQ, Tang YM, Song H, Shi SW, Yang SL, Xu WQ, Qian BQ: [Expressions of CD117 and CD11b in patients with APL at diagnosis and post-treatment]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):644-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CD117 and CD11b in patients with APL at diagnosis and post-treatment].
  • The aim of this study was to evaluate the value of CD117/CD11b phenotypic analysis to diagnosis and prognosis of acute promyelocytic leukemia (APL).
  • Three- or four-color flow cytometry with a series of 22 monoclonal antibodies and CD45/Side Scatter (SSC) gating strategy were used to identify immunophenotypic characteristics of APL as compared to CML in chronic phase (CML-CP).
  • PML/RAR alpha fusion gene was detected by using reverse-transcription polymerase chain reaction (RT-PCR) technique.
  • The results showed that MPO, CD13 and CD33 were almost expressed in all patients with APL and CML-CP whereas HLA-DR and CD34, the hematopoietic progenitor cell markers, were rarely expressed.
  • The positive rate of CD15 in APL was significantly lower than those in CML-CP (P < 0.01).
  • CD117 was positive in 78.3% of the APL cases and in none of the cases of CML-CP.
  • On the other hand, CD11b was almost positive in all cases of CML-CP, but only 16.9% of the APL cases were found positive for this antigen.
  • The CD117+ CD11b- phenotype was present in 72.3% of APL cases while none of cases with CML-CP with this phenotype.
  • CD117- CD11b+ phenotype was detected in all patients recovering from APL with CD117+ CD11b- phenotype at diagnosis and after treatment with all-trans-retinoic acid (ARTA) for 2 months.
  • PML/RAR alpha fusion gene was positive in 80.6% (25/31) of the APL cases, of which, 64% of the cases belonged to the type L while only 36% of the cases were showed type S for this fusion gene.
  • It is concluded that analysis of both CD117 and CD11b phenotype may be helpful to the diagnosis, therapy and prognosis of APL in children and adults and to differentiation of APL from recovering benign myeloid proliferation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928291.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


10. Helwig A, Klemm M, Schüttig R, Röllig C, Wassilew N, Ehninger G, Illmer T: Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res; 2007 May;31(5):703-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic-induced APL differentiation in cerebrospinal fluid.
  • Although new approaches have dramatically improved, the treatment of acute promyelocytic leukemia (APL) involvement of the central nervous system (CNS) confers a bad prognosis in the disease.
  • Here, we report a patient who was diagnosed with relapsed APL preferentially involving the CNS.
  • Since arsenic trioxide could be identified in the CNS, we provide evidence that the drug can cross the blood-brain barrier and can be used for treatment of extramedullary APL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Brain Neoplasms / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use
  • [MeSH-minor] Adult. Cell Differentiation. Cerebrospinal Fluid / cytology. Female. Humans. Leukocytes / pathology. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876245.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


11. López-Pedrera C, Cuadrado MJ, Herández V, Buendïa P, Aguirre MA, Barbarroja N, Torres LA, Villalba JM, Velasco F, Khamashta M: Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum; 2008 Sep;58(9):2835-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Antiphospholipid antibodies (aPL) are closely related to the development of thrombosis, but the exact mechanism(s) leading to thrombotic events remains unknown.
  • As controls, we studied patients with thrombosis but without aPL, and age- and sex-matched healthy subjects.
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Antibodies, Antiphospholipid / immunology. Anticoagulants / immunology. Anticoagulants / metabolism. Autoantibodies / immunology. Autoantibodies / metabolism. Autoimmunity / immunology. Blotting, Western. Cells, Cultured. Electrophoresis, Gel, Two-Dimensional. Female. Flow Cytometry. Humans. Male. Middle Aged. Proteomics. RNA, Messenger / immunology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric


12. Roy S, Mehta V, Suri R, Rath G, Dhuria R, Das S: Bitendinous insertion of abductor pollicis longus coexistent with a rare accessory antebrachial muscle: clinico-anatomical considerations. Clin Ter; 2010;161(2):159-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports of the anomalous orientation of the musculature of the fi rst osseofi brous extensor compartment of the wrist are not uncommon; especially that of Abductor Pollicis Longus (APL) muscle.
  • In this report, we highlight a unique variation in the APL muscle of the left side in an adult male cadaver.
  • The present anomaly consisted of a bitendinous insertion of APL on the base of the fi rst metacarpal, complemented by an additional muscle belly arising from the fascia covering Extensor Carpi Radialis Longus (ECRL).
  • Such multiple tendons of APL are benefi cial clinically in providing additive support to the fi rst carpo-metacarpal joint and act as effective aids in tendon transfers and reconstructive procedures of the hand.
  • Thus, it is imperative for surgeons and clinicians to acquire a prior substantial knowledge of such anatomical variants of APL before attempting any treatment of this region.
  • [MeSH-minor] Adult. Cadaver. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499032.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P, European APL Group: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia; 2005 Feb;19(2):230-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
  • We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic acid (ATRA) and of maintenance with ATRA and/or low-dose chemotherapy.
  • The 4-year incidence of relapse was 15.6% in adults older than 60 and 23.2% in younger adults although most elderly patients received less intensive consolidation chemotherapy.
  • APL in elderly patients appears as sensitive to ATRA-Chemotherapy based regimen as in younger adults.
  • Less favorable outcome is mainly due to an increase of early deaths and to toxicity of consolidation treatment, strongly suggesting a beneficial role for less intensive consolidation chemotherapy and possibly introduction of arsenic derivates in the treatment of APL in the elderly.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Europe. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565164.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


14. Stafford KM, Moore SE, Laidre KL, Heide-Jørgensen MP: Bowhead whale springtime song off West Greenland. J Acoust Soc Am; 2008 Nov;124(5):3315-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Songs recorded in Disko Bay are from an area where approximately 85% of the whales have been determined to be adult females.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19045814.001).
  • [ISSN] 1520-8524
  • [Journal-full-title] The Journal of the Acoustical Society of America
  • [ISO-abbreviation] J. Acoust. Soc. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


15. Aljurf M, Al Qurashi F, Al Mohareb F, Sahovic E, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Owaidah T, Iqbal A, Zaidi SZ, Nurgat ZA, Sanz M, Chaudhri N: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. Med Oncol; 2010 Sep;27(3):702-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
  • Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy.
  • In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Ambulatory Care. Clinical Trials as Topic / statistics & numerical data. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Factor VIII / therapeutic use. Female. Fibrinogen / analysis. Fibrinogen / therapeutic use. Hemorrhage / chemically induced. Hemorrhage / drug therapy. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Tretinoin / administration & dosage. Tretinoin / adverse effects. Young Adult

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 1;80(9):2176-81 [1421389.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1722-7 [8231241.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3330-7 [9363862.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Haematologica. 1987 Mar-Apr;72(2):151-5 [3114070.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • (PMID = 19669610.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / cryoprecipitate coagulum; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; 9001-27-8 / Factor VIII; 9001-32-5 / Fibrinogen; ZRP63D75JW / Idarubicin
  •  go-up   go-down


16. Sanmarco M, Bardin N, Camoin L, Beziane A, Dignat-George F, Gamerre M, Porcu G: Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci; 2007 Jun;1108:457-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this prospective study was to assess the prevalence of antiphospholipid antibodies (aPL) in women who had undergone in vitro fertilization (IVF) and the relationship between aPL and IVF outcome.
  • Out of the 101 infertile women, 40 were persistently positive for aPL, showing a prevalence significantly higher than in controls (39.6% versus 5%, P < 0.0001).
  • Among aPL, aPE were found with a significantly higher prevalence compared with LA, aCL, and aP2GPI (67.5% versus 0%, 15%, and 40%, respectively).
  • Interestingly, aPE were found in 70% of the cases in the absence of the other aPL.
  • The predominant isotype of aPL was IgA, in particular for abeta2GPI.
  • Finally, no significant association was found between the presence of aPL and IVF outcome.
  • This prospective study shows aPE as the most prevalent aPL in infertile women and IgA as more common than IgG and IgM.
  • However, our results do not support an association between aPL and IVF outcome.
  • [MeSH-minor] Adolescent. Adult. Cardiolipins / immunology. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Lupus Coagulation Inhibitor / immunology. Phosphatidylethanolamines / immunology. Prevalence. Treatment Outcome. beta 2-Glycoprotein I / immunology

  • MedlinePlus Health Information. consumer health - Infertility.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894010.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Cardiolipins; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / Phosphatidylethanolamines; 0 / beta 2-Glycoprotein I; 39382-08-6 / phosphatidylethanolamine
  •  go-up   go-down


17. Lu J, Jiang H, Jiang Q, Bao L, Lu XJ, Zhang Y, Lin W, Liu YR, Huang XJ, Jiang B: [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol]. Zhonghua Yi Xue Za Zhi; 2008 Aug 19;88(32):2254-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
  • OBJECTIVE: To analyze the effect of additional chromosome abnormalities on the prognosis and the clinical manifestations of acute promyelocytic leukemia (APL) and the reaction of the patients with additional chromosomes to the treatment of combination of red arsenic sulfide, all trans-retinoic acid (ATRA) and anthracyclin.
  • METHODS: The clinical data of 158 patients with newly diagnosed APL who were treated with combination of red arsenic sulfide, ATRA, and anthracyclin were analyzed retrospectively.
  • RESULTS: The frequency of additional chromosome abnormalities in the APL patients was 18.4%, and trisomy 8 and i17q- were the most to be seen.
  • The complete remission rate of the patients with additional chromosome abnormality was 75.9%, not significantly lower than that of those without additional chromosome abnormality (90.7%), and the relapse rate and incidence rate of central nervous system leukemia were 13.8% and 17.2%, both higher, but not significantly, than those of the patients without additional chromosome abnormality (6.2% and 6.2% respectively) (all P > 0.05).
  • CONCLUSION: Additional chromosome abnormality does not significantly influence the prognosis of APL treated with combination of red arsenic sulfide, ATRA, and anthracyclin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Anthracyclines / administration & dosage. Arsenicals / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Sulfides / administration & dosage. Treatment Outcome. Tretinoin / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRISULFIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087672.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Arsenicals; 0 / Sulfides; 44SIJ800OX / arsenic trisulfide; 5688UTC01R / Tretinoin
  •  go-up   go-down


18. Xia J, Yuan M, Xu HW, Zhang L, Du XP, Liu YH, Yang QD: Association between Val/Leu(247) polymorphism of apolipoprotein H and cerebral infarction in a Chinese population. J Thromb Thrombolysis; 2009 Aug;28(2):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Antiphospholipid antibodies (aPL) are considered to be a cause of an acquired hypercoagulable state leading to cerebral infarction (CI).
  • Apolipoprtein H (apoH) is an important target antigen for aPL and thus apoH polymorphisms may influence aPL production and the development of CI.
  • The presence of aPL was detected by ELISA utilizing irradiated ELISA plates.
  • RESULTS: Our results demonstrated an association between the Val/Leu(247) polymorphism of apoH gene and aPL in CI patients.
  • The frequency of V allele was significantly higher in aPL-positive CI patients compared with control group (chi(2) = 6.864, P < 0.05).
  • VL genotype frequency was also significantly higher in aPL-positive CI group compared with control group (chi(2) = 13.879, P < 0.05) and aPL-negative CI group (chi(2) = 5.567, P < 0.05).
  • CONCLUSIONS: The Val(247) allele of apoH gene is significantly associated with the presence of aPL in Chinese patients with CI.
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Case-Control Studies. China / epidemiology. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Polymorphism, Genetic. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1997 Jul;100(1):57-62 [9225969.001]
  • [Cites] Ann Hum Genet. 2004 Jul;68(Pt 4):285-99 [15225155.001]
  • [Cites] Hokkaido Igaku Zasshi. 2001 Sep;76(5):289-98 [11593753.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):471-4 [12571857.001]
  • [Cites] Eur J Biochem. 2003 Jan;270(2):230-8 [12605674.001]
  • [Cites] Neurology. 2001;57(5 Suppl 2):S24-30 [11552051.001]
  • [Cites] Lupus. 2005;14(6):440-4 [16038107.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):457-62 [7507506.001]
  • [Cites] Cerebrovasc Dis. 2005;20 Suppl 2:53-67 [16327254.001]
  • [Cites] Neurology. 2001 Apr 24;56(8):997-1008 [11339244.001]
  • [Cites] Neurology. 1993 Oct;43(10):2069-73 [8413969.001]
  • [Cites] Eur J Biochem. 1999 Jan;259(1-2):435-40 [9914524.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1655-61 [10446865.001]
  • [Cites] Autoimmun Rev. 2007 Sep;6(8):547-52 [17854747.001]
  • [Cites] Cerebrovasc Dis. 2005;20 Suppl 2:75-83 [16327256.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1066-72 [12648080.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 1999 Jul;57(5-6):351-9 [10480489.001]
  • [Cites] Lupus. 2006;15(4):218-22 [16686261.001]
  • [Cites] Clin Rheumatol. 2007 Mar;26(3):302-7 [16724168.001]
  • [Cites] Rom J Intern Med. 2007;45(2):201-4 [18333375.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):791-7 [9843173.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):721-3 [10501418.001]
  • [Cites] Thromb Haemost. 1995 Oct;74(4):1185-90 [8560433.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):212-8 [15641049.001]
  • [Cites] Thromb Res. 2004;114(5-6):489-99 [15507283.001]
  • [Cites] Cerebrovasc Dis. 2002;13 Suppl 1:7-11 [11803181.001]
  • [Cites] Intern Med. 2006;45(17):1017-8 [17016003.001]
  • (PMID = 18777117.001).
  • [ISSN] 1573-742X
  • [Journal-full-title] Journal of thrombosis and thrombolysis
  • [ISO-abbreviation] J. Thromb. Thrombolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


19. Valentinov Monov S, Valentinova Monova D: Neuropsychiatric lupus in patients with lupus glomerulonephritis. Med Pregl; 2007;60 Suppl 2:70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent clinical manifestations are cognitive dysfunction (52.94%), headache (29.41%), psychoses (17.65%), epileptic seizures (20.59%) etc., and the most common cognitive deficit is related to impairment of the memory.
  • The presented study describes the correlations between the immunologic deviations (antiribosomal P-antibodies, aPL, aSm, aC1q), MMP-9, AT III and the NP injuries.
  • [MeSH-minor] Adult. Cognition Disorders / etiology. Epilepsy / etiology. Female. Headache Disorders, Secondary / etiology. Humans. Male. Neurocognitive Disorders / etiology


20. Buckingham KL, Stone PR, Smith JF, Chamley LW: Antiphospholipid antibodies in serum and follicular fluid--is there a correlation with IVF implantation failure? Hum Reprod; 2006 Mar;21(3):728-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: In 19.2% of 99 women undergoing IVF, at least one aPL was detected in their serum and/or follicular fluids, but the antibody levels in follicular fluid were not higher than in serum.
  • [MeSH-minor] Adult. Biomarkers / analysis. Biomarkers / blood. Embryo Implantation. Female. Humans. Infant, Newborn. Pregnancy. Treatment Failure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Reprod. 2007 Nov;22(11):3043-4; author reply 3044-5 [17911383.001]
  • (PMID = 16253967.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Biomarkers
  •  go-up   go-down


21. Sirotakova M, Figus A, Elliot D: A new abductor pollicis longus suspension arthroplasty. J Hand Surg Am; 2007 Jan;32(1):12-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to introduce a variation of the abductor pollicis longus (APL) sling arthroplasty and to determine its efficacy in comparison with other tendon sling arthroplasty procedures.
  • METHODS: Between January 1999 and December 2003, 104 trapeziectomies in 74 consecutive patients (30 bilateral cases) were performed using a new APL sling arthroplasty.
  • After 12 months, the 65 patients with successful trapeziectomies and APL sling remained pain-free.
  • CONCLUSIONS: This modified APL sling arthroplasty is a new and effective way of creating a suspension sling with the APL tendon after trapeziectomy, with results comparable or better than other published methods, for the treatment of osteoarthritis of the first carpometacarpal joint.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pain Measurement. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218171.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Horai Y, Watanabe H, Miyamura T, Takahama S, Hirata A, Nakamura M, Ando H, Minami R, Yamamoto M, Suematsu E: Clinical analysis of cerebrospinal fluid interleukin-6 in neuropsychiatric systemic lupus erythematosus. Fukuoka Igaku Zasshi; 2010 Feb;101(2):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, a group of NPSLE patients positive for antiphospholipid antibodies (aPL) showed lower CSF IL-6 than the patients negative for aPL.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560477.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-6
  •  go-up   go-down


23. Saha SP, Bhattacharjee N, Ganguli RP, Sil S, Patra KK, Sengupta M, Barui G, Goswami BK: Prevalence and significance of antiphospholipid antibodies in selected at-risk obstetrics cases: a comparative prospective study. J Obstet Gynaecol; 2009 Oct;29(7):614-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective comparative study we screened 112 women with a past history either of pre-eclampsia, eclampsia, recurrent abortion, IUGR, IUFD or abruptio placentae, with no apparent aetiology and a demographically matched cohort of 106 women having a past history of uncomplicated pregnancy outcome for the presence of antiphospholipid antibodies (aPL) and their significance.
  • In the former group, the prevalence of aPL ranged from 10-46.87% compared with 8.49% in the later group.
  • In women with the presence of aPL, the incidence of pre-eclampsia, early onset pre-eclampsia and abruptio placentae were 25%, 14.58% and 18.75%, respectively.
  • Fetal morbidity rates were also higher in the mothers with aPL positivity, the incidence of IUGR was 27.08% and oligohydramnios was 33.33% in them.
  • All these complications were statistically significant when compared with those of aPL negative mothers.
  • [MeSH-minor] Adult. Antiphospholipid Syndrome / epidemiology. Female. Humans. Incidence. India / epidemiology. Pregnancy. Pregnancy Outcome. Prevalence. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757265.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Lupus Coagulation Inhibitor
  •  go-up   go-down


24. Okuma H, Kitagawa Y, Takagi S: Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients. Clin Dev Immunol; 2010;2010:439230
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid syndrome is characterized by arterial or venous thrombosis and the presence of antiphospholipid antibodies (aPL).
  • Among the 250 patients, 13.6% (34/250) were positive for either PI or PS, and 6.8% (17/250) were positive for both.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Antinuclear / blood. Carotid Arteries / pathology. Clinical Trials as Topic. Female. Humans. Japan. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / immunology. Male. Middle Aged. Risk Factors


25. Sultana TA, Abdul Mottalib M, Islam S, Khan MA, Choudhury S: Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh. Bangladesh Med Res Counc Bull; 2008 Apr;34(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nested reverse-transcriptase polymerase chain reaction (rt-PCR) was performed on 58 leukemia patients at BIRDEM Laboratory, as a pioneering work in Bangladesh.
  • Thirty of themwere examined for the presence of BCR-ABL being clinically and morphologically diagnosed as chronic myeloid leukemia (CML) and 28 for PML-RARalpha fusion transcripts being clinically and morphologically diagnosed as acute promyelocytic leukemia (APL/ AML M3).
  • The cases were selected for targeted therapy with imatinib mesylate and all-Trans retinoic acid (ATRA) to treat CML and APL respectively.
  • Positive results for PML-RARalpha were found for 12 out of 14 (85.70%) untreated cases and 11 out of 16 (68.75%) treated cases.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Promyelocytic, Acute / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Bangladesh. Benzamides. Child. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Prospective Studies. Pyrimidines / therapeutic use. Treatment Outcome. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783070.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


26. Miesbach W, Matthias T, Scharrer I: Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci; 2005 Jun;1050:250-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Venous or arterial thrombosis, abortion, and the presence of antiphospholipid antibodies (aPL) define the criteria for the antiphospholipid syndrome (APS).
  • We investigated the presence of antibodies to thrombin (Thr) in patients with aPL and reviewed their clinical manifestations.
  • IgG and IgM titers of aPL were measured by ELISA (Aesku.Diagnostics, Wendelsheim, Germany).
  • Anti-thrombin antibodies were found in 20% of patients with aPL; 67% of these patients were admitted with thrombotic manifestations of APS.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / blood. Antibodies, Antiphospholipid / blood. Enzyme-Linked Immunosorbent Assay. Female. Glycoproteins / blood. Glycoproteins / immunology. Humans. Immunoglobulin G / analysis. Immunoglobulin M / analysis. Lupus Coagulation Inhibitor / analysis. Male. Middle Aged. Prothrombin / immunology. Sensitivity and Specificity. Thrombosis / immunology. Thrombosis / pathology. beta 2-Glycoprotein I

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014540.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I; 9001-26-7 / Prothrombin; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


27. Yang B, Chi XH, Lu XC, Han WD, Yu L, Lou FD: [Lrp16 gene expression in leukemia cell lines and bone marrow cells of leukemia patients and its clinical implication]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug;17(4):857-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lrp16 gene expression in leukemia cell lines and bone marrow cells of leukemia patients and its clinical implication].
  • This study was purposed to investigate lrp16 gene expression in leukemia cell lines and bone marrow cells of leukemia patients and explore the relationship between lrp16 gene expression and development of leukemia.
  • Reverse transcriptase-polymerase chain reaction (RT-PCR) was employed to test the lrp16 mRNA expression in 4 leukemia cell lines, including K562 (CML), HL-60 (APL), MOLT4 (ALL) and U937 cell lines, as well as in bone marrow-derived cells from 115 patients with leukemia.
  • The effect of lrp16 gene expression on genesis and progression of leukemia was analyzed according to clinicopathological features.
  • The results indicated that positive expression of lrp16 mRNA was found in all 4 leukemia cell lines.
  • For leukemia patients, the positive expression rate of lrp16 mRNA in all AML patients was 38% (16/42), in which the positive rates in AML patients with complete remission (CR) and AML patients without remission were 13% (4/30) and 100% (12/12) respectively.
  • The positive rate of lrp16 mRNA in CLL patients was 31% (7/22), in which the positive rate in CLL patients with CR and CLL patients without remission were 11% (2/17) and 100% (5/5) respectively.
  • There was no difference of lrp16 gene expression between leukemia subtypes, but there was statistical significant difference in lrp16 gene expression between CR patients and non CR patients (p < 0.001).
  • It is concluded that the lrp16 gene is a leukemic oncogene and closely relates to genesis and progression of leukemia, which may be an indicator for evaluating clinical efficacy of leukemia therapy.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698216.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / LRP16 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


28. Ibrahim FA, Yassin MA, El-Ayoubi HR, Alhiji IA, Albinali AS, Almansour SM, Qafoud FM: Clinico-pathological profile of acute promyelocytic leukaemia at Al-Amal Oncology-Haematology Centre, Qatar. East Mediterr Health J; 2010 Sep;16(9):958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological profile of acute promyelocytic leukaemia at Al-Amal Oncology-Haematology Centre, Qatar.
  • This cases series describes the profile of adult patients with acute promyelocytic leukaemia (APt) at a referral hospital in Qatar.
  • Of 34 acute myeloid leukaemia (AML) cases diagnosed, 11(32%) were classified as APt.
  • Translocation t(15;17) was detected in 63% of cases.
  • APL constitutes a high proportion of AML cases in Qatar, with considerable morphological heterogeneity and a oredominance of APL variants with unfavourable oresenting features.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / epidemiology. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Anemia / epidemiology. Anemia / etiology. Bone Marrow Examination. Cancer Care Facilities. Cytogenetic Analysis. Female. Flow Cytometry. Genetic Variation / genetics. Humans. Immunophenotyping. Karyotyping. Leukocytosis / epidemiology. Leukocytosis / etiology. Male. Middle Aged. Population Surveillance. Qatar / epidemiology. Thrombocytopenia / epidemiology. Thrombocytopenia / etiology. Translocation, Genetic. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21218723.001).
  • [ISSN] 1020-3397
  • [Journal-full-title] Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ
  • [ISO-abbreviation] East. Mediterr. Health J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


29. Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Döhner K, Fröhling S, Döhner H, AML Study Group (AMLSG): High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia; 2005 Jun;19(6):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
  • The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL).
  • In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Mitoxantrone / administration & dosage. Tretinoin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Remission Induction. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2005 Jun;19(6):913-5 [15843820.001]
  • (PMID = 15843821.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZRP63D75JW / Idarubicin; AIDA protocol; MAC chemotherapy protocol
  •  go-up   go-down


30. Di Simone N, Di Nicuolo F, D'Ippolito S, Castellani R, Tersigni C, Caruso A, Meroni P, Marana R: Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod; 2010 Aug 1;83(2):212-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (aPL) represent an important risk factor for thrombosis and recurrent miscarriage in patients with antiphospholipid syndrome (APS).
  • The mechanisms of aPL-mediated pregnancy failure have been researched.
  • Previous studies demonstrated that aPL bind trophoblast cells, reducing proliferation, human chorionic gonadotrophin release, and in vitro invasiveness.
  • Recent data suggest that aPL are also able to react with human decidual cells, inducing a proinflammatory phenotype.
  • Since angiogenesis is a critical component of normal placentation, the purpose of our study was to evaluate the role of aPL on human endometrial angiogenesis.
  • For this reason, we investigated the effect of aPL on in vitro endometrial endothelial cell (HEEC) angiogenesis, VEGF secretion by ELISA, matrix metalloproteinases (MMPs) activity by gelatin zymography, and DNA binding activity of NFKB by a sensitive multiwell colorimetric assay.
  • Furthermore, we performed experiments to study whether aPL affects in vivo angiogenesis in a murine model.
  • We found that aPL significantly decrease the number and the total length of the tubules formed by HEEC on in vitro Matrigel assay and reduce newly formed vessels in aPL-inoculated mice.
  • Moreover, aPL reduce significantly both VEGF and MMPs production and, at the nuclear level, NFKB DNA binding activity.
  • From our results, it appears that aPL are associated with an inhibition of angiogenesis, suggesting further additional mechanisms to explain the defective placentation in the APS.
  • [MeSH-minor] Abortion, Habitual / etiology. Adult. Animals. Antiphospholipid Syndrome / complications. Cells, Cultured. DNA / metabolism. Endothelial Cells / immunology. Female. Flow Cytometry. Humans. Matrix Metalloproteinase Inhibitors. Matrix Metalloproteinases / metabolism. Mice. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Pregnancy. Vascular Endothelial Growth Factor A / secretion

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393166.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Vascular Endothelial Growth Factor A; 9007-49-2 / DNA; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


31. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foà R, Lo Coco F, Peschle C, Testa U: TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica; 2005 May;90(5):612-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
  • The present study was designed to evaluate the sensitivity to TRAIL-induced apoptosis in acute myeloblastic leukemias (AML).
  • DESIGN AND METHODS: TRAIL/TRAIL receptor (TRAIL-R) expression and sensitivity to TRAIL-mediated apoptosis were explored in 79 AML patients, including 17 patients with acute promyelocytic leukemia (APL).
  • RESULTS: In non-APL AML we observed frequent expression of TRAIL decoy receptors (TRAIL-R3 and TRAIL-R4), while TRAIL-R1 and TRAIL-R2 expression was restricted to AML exhibiting monocytic features.
  • APL express membrane-bound TRAIL on their surface and exhibit a pattern of TRAIL-R expression similar to that observed in the other types of AML.
  • Before, during and after retinoic acid treatment APL cells are TRAIL-resistant.
  • The induction of granulocytic maturation of APL cells by retinoic acid was associated with a marked decline of TRAIL expression.
  • INTERPRETATION AND CONCLUSIONS: The analysis of experimental APL models (i.e., U937 cells engineered to express PML/RAR-Eo and NB4 cells) provided evidence that PML/RAR-Eo expression was associated with downmodulation of TRAIL-R1 and with resistance to TRAIL-mediated apoptosis.
  • We suggest that AML blasts, including APL blasts, are resistant to TRAIL-mediated apoptosis, a phenomenon seemingly related to the expression of TRAIL decoy receptors on these cells.
  • Finally, APL blasts express membrane-bound TRAIL that could confer an immunologic privilege to these cells.
  • [MeSH-major] Apoptosis / drug effects. Drug Resistance, Neoplasm / genetics. Leukemia, Myeloid / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology. Receptors, Tumor Necrosis Factor / physiology. Tumor Necrosis Factor Decoy Receptors / physiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Agents / pharmacology. Caspase 3 / analysis. Caspase 8 / analysis. Cell Differentiation / drug effects. Cell Membrane / metabolism. Cytarabine / pharmacology. Etoposide / pharmacology. Female. GPI-Linked Proteins. Granulocytes / drug effects. HL-60 Cells / pathology. Humans. Hydroxyurea / pharmacology. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / pathology. Male. Middle Aged. Monocytes / drug effects. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / physiology. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / physiology. Tretinoin / pharmacology. Tumor Cells, Cultured / drug effects. Tumor Stem Cell Assay. U937 Cells / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921376.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GPI-Linked Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Fusion Proteins; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFRSF10C protein, human; 0 / TNFRSF10D protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


32. Forastiero RR, Martinuzzo ME, de Larrañaga GF: Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus; 2005;14(2):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) in patients with thromboembolic complications.
  • In APS, most aPL are autoantibodies to beta2-glycoprotein I and prothrombin, which play a major role in the APS pathogenesis.
  • Nevertheless, antibodies with the same antigen specificity are also found in aPL patients with leprosy, in whom thromboembolic complications are uncommon.
  • We measured the circulating levels of TF, interleukin 6 (IL-6), IL-6 receptor (sIL-6R), tumor necrosis factor (TNF-alpha) and interferon gamma (IFN-gamma) in 83 patients with autoimmune aPL (42 with and 41 without clinical features of definite primary APS), 48 leprosy patients (33 with aPL) and 48 normal controls.
  • There was a trend (P = 0.06) to higher median sTF in patients with autoimmune aPL (139 pg/mL) compared with leprosy patients (103.5 pg/mL) and controls (123 pg/mL).
  • In addition, the frequency of raised sTF levels (> 187 pg/mL) was significantly higher in the group with autoimmune aPL [22.9% (APS 21.4%, non-APS 24.4%)] but not in leprosy (10.4%) compared with controls (4.2%).
  • Leprosy patients with aPL, however, had increased TNF-alpha and IFN-gamma but normal IL-6 levels.
  • Levels of sIL-6R did not differ between controls and either patients with autoimmune aPL or leprosy.
  • The different cytokine profiles as well as differences in circulating levels of TF might contribute to the high thrombotic risk found in patients with autoimmune aPL but not in leprosy related aPL patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Antiphospholipid / blood. Child. Female. Humans. Male. Middle Aged. Receptors, Interleukin-6 / blood


33. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol; 2010 Aug 1;28(22):3636-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
  • PURPOSE: To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML).
  • PATIENTS AND METHODS: We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study Group (AMLSG) treatment trials AML HD98A and APL HD95 for mutations in exon 4 of IDH1 and IDH2.
  • [MeSH-major] Isocitrate Dehydrogenase / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Mutation. Nuclear Proteins / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Tandem Repeat Sequences

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567020.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


34. Pendino F, Hillion J, Dudognon C, Delaunay J, Mourah S, Podgorniak MP, Lafon I, Chomienne C, Lanotte M, Dombret H, Rousselot P, Ségal-Bendirdjian E: Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia; 2006 Apr;20(4):599-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.
  • Recently, we have shown that long-term treatment with all-trans retinoic acid (ATRA), a compound clinically approved for differentiation therapy of acute promyelocytic leukemia (APL), represses hTERT in differentiation-resistant APL cell lines leading to telomere shortening and death.
  • In contrast to differentiation-therapy, which is only successful in this subtype of leukemia, the telomerase-targeted pathway could also be of use in non-APL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. DNA-Binding Proteins / antagonists & inhibitors. Leukemia, Myeloid / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Retinoids / pharmacology. Telomerase / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Death / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Leukemic / drug effects. Humans. Male. Middle Aged. RNA, Messenger / drug effects. RNA, Messenger / genetics. Structure-Activity Relationship. Telomere / drug effects. Telomere / genetics. Treatment Outcome. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482212.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Retinoids; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


35. Choughule A, Polampalli S, Amre P, Shinde S, Banavali S, Prabhash K, Nair R, Subramanian PG, Gujral S, Parikh PM: Identification of PML/RARalpha fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. Genet Mol Res; 2009;8(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PML/RARalpha fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization.
  • Acute promyelocytic leukemia (APL) is characterized by a reciprocal translocation, t(15;17)(q22;q11-21), resulting in the fusion of the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARalpha) genes.
  • These masked PML/RARalpha fusions can be identified by molecular analyses, such as reverse transcriptase-polymerase chain reaction (RT-PCR) or fluorescence in situ hybridization (FISH).
  • Approximately 5 to 10% of all APL cases reported do not show PML/RARalpha fusion transcripts, even with dual-colored FISH.
  • We report three of 40 diagnosed APL cases that showed morphological, cytochemical, and immunophenotypic features of hypergranular APL, but did not show a PML/RARalpha fusion signal or any of its variants, on FISH.
  • Conventional karyotyping showed other clonal aberrations in these cases, but failed to show t(15;17) or any other variants or complex translocations.
  • [MeSH-major] Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224461.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


36. Wang L, Li Y, Wang PP, Lu XL, Wang BX: [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):324-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
  • The aim of study was to investigate the effects of arsenic trioxide (As(2)O(3)) on cell cycle and apoptosis of APL cells, as well as changes of P27(Kip1), endogenous TGF-beta1, cyclin E and bcl-2, and to explore the relationship between expression of P27(Kip1) and apoptosis induced by As(2)O(3).
  • The apoptosis and cell cycle changes of APL cells treated with As(2)O(3) were detected by morphology and flow cytometry respectively, the protein and mRNA expressions of P27(Kip1), TGF-beta1, cyclin E and BCL-2 were measured by immunohistochemistry and RT-PCR.
  • The results indicated that As(2)O(3) induced APL cell apoptosis in vitro, and cell cycle was arrested at G(1) phase.
  • Protein and mRNA expressions of P27(Kip1) and TGF-beta1 of APL cells after treatment with As(2)O(3) increased, accompanying with decrease of cyclin E, bcl-2 protein and mRNA expressions.
  • It is concluded that the apoptosis of APL cells is induced by As(2)O(3), and the cell cycle is arrested at G(1) phase.
  • Apoptosis of APL cells induced by As(2)O(3) may be caused by up-regulating TGF-beta1 and P27(Kip1), which is antagonistic to cyclin E and BLC-2, leading to arrest of cell cycle at G(1) phase.

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379560.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / CDKN1B protein, human; 0 / Oxides; 0 / Transforming Growth Factor beta1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


37. Fukushima S, Terasaki M, Tajima Y, Shigemori M: Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report. J Neurosurg; 2006 Dec;105(6):912-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report.
  • Granulocytic sarcomas are rare tumors that occur primarily in patients with acute myelogenous leukemia or other myeloproliferative disorders, are seldom seen in patients with acute promyelocytic leukemia (APL), and have never been reported to occur in the cerebellum.
  • The authors describe the case of a patient with APL who harbored a hemorrhagic granulocytic sarcoma in the cerebellum.
  • Bone marrow samples showing infiltration by leukemic blast cells and data from hematological tests led to a diagnosis of APL.
  • Although no cytogenetic abnormality was present, fluorescence in situ hybridization detected a chimeric fusion of PML and RARA.
  • This is the first report to document a granulocytic sarcoma in the cerebellum as the primary presentation in a patient with APL and abnormal coagulation.
  • Although central nervous system complications in patients with APL are rare, the data in this case highlight the need for individualized treatment when such conditions occur.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Cerebral Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Bone Marrow / pathology. Cerebellar Ataxia / etiology. Cerebellum / pathology. Chimera / genetics. Female. Gene Fusion / genetics. Granulocyte Precursor Cells / pathology. Humans. Inclusion Bodies / pathology. Karyotyping. Magnetic Resonance Imaging. Receptors, Retinoic Acid / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405265.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha
  •  go-up   go-down


38. Wielosz E, Dryglewska M, Majdan M: Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin Rheumatol; 2009 Aug;28(8):955-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid (aPL) antibodies are often detected in systemic autoimmune diseases.
  • The aim of the study was to examine the correlation between the presence of aPL and certain markers of renal function in systemic sclerosis (SSc).
  • As independent variables, aPL of either type were inserted in addition to disease duration and age.
  • Our study suggests the relationship between kidney involvement and the positivity for some aPL in patients with SSc.
  • [MeSH-minor] Adult. Aged. Creatinine / blood. Cystatin C / blood. Female. Glomerular Filtration Rate. Humans. Male. Middle Aged. Oxidative Stress. Proteinuria. Young Adult

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Rheumatol. 2009 Aug;28(8):881-2 [19513779.001]
  • [Cites] Indian J Med Sci. 2007 Feb;61(2):91-6 [17259688.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 2:S2 [17767740.001]
  • [Cites] Z Rheumatol. 2004 Dec;63(6):446-50 [15605207.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):771-4 [12860735.001]
  • [Cites] Rheumatol Int. 2007 Sep;27(11):1087-9 [17429639.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50 Suppl 1:228-31 [16119673.001]
  • [Cites] Autoimmunity. 1995;20(1):1-7 [7578856.001]
  • [Cites] Clin Exp Immunol. 1988 Sep;73(3):456-60 [2974767.001]
  • [Cites] Semin Arthritis Rheum. 2006 Jun;35(6):360-7 [16765713.001]
  • [Cites] Rheumatol Int. 2008 Jul;28(9):919-23 [18320193.001]
  • [Cites] J Rheumatol. 1991 Dec;18(12):1833-6 [1839040.001]
  • [Cites] J Rheumatol. 1988 Feb;15(2):202-5 [3361530.001]
  • [Cites] J Rheumatol. 2000 Jun;27(6):1450-2 [10852269.001]
  • [Cites] Arthritis Res Ther. 2003;5(2):80-93 [12718748.001]
  • [Cites] J Rheumatol. 2005 Apr;32(4):649-55 [15801020.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2569-79 [15334471.001]
  • [Cites] G Ital Nefrol. 2007 Jul-Aug;24(4):295-310 [17659501.001]
  • [Cites] Int Urol Nephrol. 2006;38(2):381-5 [16868715.001]
  • [Cites] Clin Rev Allergy Immunol. 2009 Jun;36(2-3):131-40 [19048414.001]
  • [Cites] Arthritis Rheum. 1998 Sep;41(9):1613-9 [9751093.001]
  • [Cites] Clin Dermatol. 1994 Apr-Jun;12(2):253-8 [8076263.001]
  • [Cites] Clin Exp Rheumatol. 2005 Mar-Apr;23(2):199-204 [15895890.001]
  • [Cites] Nihon Jinzo Gakkai Shi. 1998 May;40(4):295-300 [9654914.001]
  • [Cites] Arthritis Rheum. 1989 Sep;32(9):1128-34 [2775321.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]
  • [Cites] Clin Exp Immunol. 1996 Sep;105(3):475-9 [8809137.001]
  • (PMID = 19437088.001).
  • [ISSN] 1434-9949
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Cystatin C; AYI8EX34EU / Creatinine
  •  go-up   go-down


39. Dore AI, Santana-Lemos BA, Coser VM, Santos FL, Dalmazzo LF, Lima AS, Jacomo RH, Elias J Jr, Falcão RP, Pereira WV, Rego EM: The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol; 2007 Nov;82(5):1340-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia.
  • The use of all trans-retinoic acid (ATRA) is the basis of treatment of acute promyelocytic leukemia (APL) and represents the paradigm of differentiation therapy.
  • As leukocyte extravasation is a key event in DS pathogenesis, we analyzed the association between the polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) of ICAM-1 and Exon 3 (L125V) of PECAM-1 genes with DS development in APL patients treated with ATRA and anthracyclines.
  • DS was diagnosed in 23/127 (18.1%) APL patients at an average of 11.5 days after the start of ATRA.
  • Our results suggest that susceptibility to DS in APL patients may be influenced by genetic variation in adhesion molecule loci.
  • [MeSH-major] Antigens, CD31 / genetics. Exons / genetics. Intercellular Adhesion Molecule-1 / genetics. Leukemia, Promyelocytic, Acute / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Cell Differentiation. Diagnosis, Differential. Female. Humans. Male. Syndrome. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704297.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antineoplastic Agents; 126547-89-5 / Intercellular Adhesion Molecule-1; 5688UTC01R / Tretinoin
  •  go-up   go-down


40. de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P: Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol; 2005 Jan 1;23(1):120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
  • PURPOSE: To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT) during second complete remission.
  • PATIENTS AND METHODS: Of 122 relapsing patients included in two successive multicenter APL trials who achieved hematological second complete remission (generally after a salvage regimen of all-trans-retinoic acid [ATRA] combined with chemotherapy), 73 (60%) received allogeneic (n = 23) or autologous (n = 50) SCT.
  • CONCLUSION: These retrospective data suggest that autologous SCT is very effective in APL relapsing after treatment with ATRA if performed in molecular remission.
  • Salvage with arsenic trioxyde, which has lower toxicity, should further improve the outcome of relapsing APL, especially before allogeneic SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / therapy. Salvage Therapy. Stem Cell Transplantation. Tretinoin / administration & dosage
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534358.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


41. Wei H, Tian Z, Wang XJ, Liu KQ, Zhang CP, Wang HJ, Mi YC, Wang JX: [Acute promyelocytic leukemia with CD59 deficiency]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute promyelocytic leukemia with CD59 deficiency].
  • The study was aimed to investigate whether CD59 is deficient in acute promyelocytic leukemia (APL) blast cells.
  • Expression of CD59 on APL blast cells was analysed by flow cytometry.
  • The results showed that the deficiency of CD59 expression in 12 out of 19 APL samples was found, its incidence was significantly higher than that in other acute myeloid leukemia (AML) samples (deficiency of CD59 expression in 14 of 40 non-APL AML samples, p=0.042).
  • The expression of CD59 became normal after the patients achieved complete remission (CR), which indicated that the deficient of CD59 expression was only found in APL blast cells, but also found in APL cell line NB4 cells.
  • Sequencing pig-A gene coding region of NB4 cells and one APL patient with deficiency of CD59 displayed that the mutation of pig-A gene was not observed, therefore the deficiency of CD59 expression in APL cells did not result from mutation of pig-A gene.
  • It is concluded that the deficiency of CD59 expression exists in APL blast cells more probably.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Cd59 deficiency.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129240.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD59; 0 / Membrane Proteins; 0 / phosphatidylinositol glycan-class A protein; 5688UTC01R / Tretinoin
  •  go-up   go-down


42. Sastre López A, Gago González E, Baños Gallardo M, Gómez-Huertas E, Ortega Suárez F: [All-trans retinoic acid syndrome [corrected] and renal cortical necrosis]. An Med Interna; 2007 Nov;24(11):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We described a patient with acute promyelocytic leukemia (APL) who developed all-trans retinoic acid syndrome (ATRAS).
  • ATRAS presents in patients with APL treated with all-trans retinoic acid (ATRA).
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Promyelocytic, Acute / drug therapy. Syndrome

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275266.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


43. Dimov ND, Medeiros LJ, Ravandi F, Bueso-Ramos CE: Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. Am J Clin Pathol; 2010 Mar;133(3):484-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.
  • Despite the success of the current therapy for patients with acute promyelocytic leukemia (APL), relapse occurs in up to 30% of patients.
  • The characteristics of relapsed APL are not well described.
  • We evaluated a group of APL cases at relapse and compared the clinicopathologic, immunophenotypic, molecular, and cytogenetic findings with those at initial diagnosis.
  • From a group of 207 patients with APL, in 38 patients morphologic evidence of relapse developed.
  • The size of the PML-RARalpha fusion transcript was invariable.
  • We conclude that changes in the immunophenotype and cytogenetic evidence of clonal evolution are common in APL at the time of relapse.
  • [MeSH-major] Cytogenetics. Immunophenotyping. Leukemia, Promyelocytic, Acute / pathology. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression Regulation, Leukemic / genetics. Gene Expression Regulation, Leukemic / immunology. Humans. Infant. Male. Middle Aged. Recurrence. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154288.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


44. Kalashnikova LA, Dobrynina LA, Aleksandrova EN, Novikov AA: [Neurological appearances of primary antiphospholipid syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova; 2005;(Suppl 13):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and twenty four patients (100 women, 24 men, mean age 37.5 +/- 11.3 years) with primary APS (PAPS), including 76 patients with Sneddon's syndrome and positive antibodies to phospholipids (aPL), have been studied.
  • A structure of neurological disturbances was as follows: ischemic lesions of cerebral blood flow (LCBF) which comprised stroke and transient LCBF (91%); thrombosis of brain venous sinuses (3%); epileptic seizures (24%); headache (65%); chorea (15%); visual neuropathy (9%); peripheral neuropathy (6%); multiple-sclerosis-like syndrome (10%); myasthenia syndrome (1%); syndrome of parkinsonism of non-vascular genesis (1%) and psychotic disorders (2%).
  • All the patients had aPL: aPL to cardiolipin (aCL) and/or lupus coagulant (LC) and/or aPL to phosphatidyl serine, phosphatidyl inositol, phosphatidyl ethanolamine.
  • Thus, the presence of clinical symptoms of PAPS including neurological disturbances demands an investigation of different aPL types as well as a replicate study for immunological confirmation of PAPS.

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986822.001).
  • [ISSN] 1997-7298
  • [Journal-full-title] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • [ISO-abbreviation] Zh Nevrol Psikhiatr Im S S Korsakova
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


45. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum; 2005 May;52(5):1545-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the intracellular mechanism involved in the up-regulation of tissue factor (TF) on endothelial cells (ECs) by antiphospholipid antibodies (aPL), we examined the effects of aPL on the transcription, expression, and function of TF, the expression of interleukin-6 (IL-6) and IL-8, the induction of inducible nitric oxide synthase (iNOS), and the phosphorylation of p38 MAPK on human umbilical vein ECs (HUVECs).
  • METHODS: Cultured HUVECs were treated with IgG aPL (from patients with antiphospholipid syndrome [APS]) or with control IgG (from normal human serum).
  • RESULTS: PMA, LPS, and aPL significantly increased the expression of TF compared with controls.
  • TF activity was significantly increased by treatment with IgG aPL and this effect was also inhibited by SB203580.
  • Incubation of HUVECs with aPL increased TF mRNA 2-15-fold; these effects were abrogated by SB203580.
  • IgG aPL induced significant phosphorylation of p38 MAPK and produced iNOS on HUVECs in a time-dependent manner.
  • Treatment with IgG aPL also induced increased expression of IL-6 and IL-8 on HUVECs.
  • CONCLUSION: Our data show that aPL induces significant increases in TF transcription, function, and expression, in IL-6 and IL-8 up-regulation, and in iNOS expression on HUVECs and that these processes involve phosphorylation of p38 MAPK and activation of NF-kappaB.
  • Understanding intracellular events in aPL-mediated EC activation may help in designing new targeted therapies for thrombosis in APS.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Phosphorylation. Umbilical Veins / cytology. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880836.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / G12-RR-03034; United States / NIGMS NIH HHS / GM / S02-GM-08248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 9035-58-9 / Thromboplastin; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


46. Biggioggero M, Meroni PL: The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev; 2010 Mar;9(5):A299-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (aPL) can be detected by functional (lupus anticoagulant) and/or by solid phase assays (anti-cardiolipin and anti-beta2 glycoprotein I).
  • Although detectable in 1-5% of asymptomatic apparently healthy subjects, persistent aPL are significantly associated with recurrent arterial/venous thrombosis and with pregnancy morbidity.
  • The prevalence of the syndrome with no associated systemic connective tissue diseases (primary APS) in the general population is still a matter of debate since there are no sound epidemiological studies in the literature so far. aPL display higher prevalence in systemic lupus erythematosus and rheumatoid arthritis than in other systemic autoimmune diseases.
  • However not all the aPL positive lupus patients display the clinical manifestations.
  • High prevalence of aPL has been also reported in clinical manifestations that are not formal APS classification criteria: heart valve disease, livedo reticular, nephropathy, neurological manifestations, and thrombocytopenia.
  • Ethnicity was also reported to influence the prevalence of aPL.
  • [MeSH-minor] Adult. Child. Female. Humans. Syndrome

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009. Published by Elsevier B.V.
  • (PMID = 19932199.001).
  • [ISSN] 1873-0183
  • [Journal-full-title] Autoimmunity reviews
  • [ISO-abbreviation] Autoimmun Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  • [Number-of-references] 57
  •  go-up   go-down


47. Capria S, Latagliata R, Avvisati G, Breccia M, Cimino G, Diverio D, Petti MC, Meloni G: BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. Bone Marrow Transplant; 2005 Jul;36(1):83-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / methods. Leukemia, Promyelocytic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Amsacrine / administration & dosage. Carmustine / administration & dosage. Child. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Remission Induction. Salvage Therapy / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880128.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; U68WG3173Y / Carmustine; BAVC protocol
  •  go-up   go-down


48. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH: Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood; 2007 Feb 15;109(4):1490-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paradoxical correlation between thrombosis and the lupus anticoagulant (LAC) effect is an enigmatic feature of the antiphospholipid (aPL) syndrome.
  • These results are consistent with a model in which aPL antibodies may promote thrombosis by interfering with the anticoagulant activity of AnxA5.
  • [MeSH-minor] Adult. Binding Sites / immunology. Blood Coagulation. Case-Control Studies. Epitopes. Female. Humans. Lupus Coagulation Inhibitor / blood. Male. Thrombosis / etiology

  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053060.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antibodies, Antiphospholipid; 0 / Epitopes; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


49. Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A: Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol; 2006 Oct;17(10):1553-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
  • BACKGROUND: Recently, patients with acute promyelocytic leukaemia (APL) have experienced significant clinical gains after treatment with arsenic trioxide.
  • PATIENTS AND METHODS: Of 95 newly diagnosed APL patients, 85 patients who achieved complete remission (CR) were sequentially evaluated during a 4-60 month period by conventional RT-PCR.
  • The PML-RARalpha fusion transcripts values were normalised to every 10(6) copies of G6PDH transcripts (NQ).

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831853.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Protein Isoforms; 0 / Recombinant Fusion Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 1.1.1.49 / Glucosephosphate Dehydrogenase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


50. Pascut D, Princi T, Donato M, Tamaro G, Parco S: Antiphospholipid antibodies and lipoprotein(a) in obese children. Acta Paediatr; 2009 Apr;98(4):703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases.
  • We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults.
  • RESULTS: aPL antibodies were detected in 2.65% of prepubertal and in 2.59% of pubertal obese children.
  • Considering results obtained by Lp(a) test, 4.4% of prepubertal and 5.2% of pubertal obese children and 17.5% of healthy adults were at risk for development of cardiovascular diseases.
  • Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor.
  • These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.
  • [MeSH-minor] Adolescent. Adult. Body Mass Index. Cardiovascular Diseases / blood. Case-Control Studies. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Puberty / blood. Risk Factors

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183123.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lipoprotein(a)
  •  go-up   go-down


51. Jeddi R, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, Meddeb B: [Pseudotumor cerebri with all-trans retinoic acid. A case report]. Tunis Med; 2006 Dec;84(12):827-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an uncommon complication of all-trans-retinoic acid (ATRA) therapy in children treated for acute promyelocytic leukaemia (APL).
  • Its occurrence is rare among adult patients with APL and treated with ATRA .
  • We report a case of an adult with APL who developed PC during induction therapy with ATRA-PC was managed with repeated lumbar punctures and corticotherapy.
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Pseudotumor cerebri.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17288291.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


52. Zhang XH, Hu Y, Bao L, Jiang Q, Yang LH, Lu XJ, Hong M, Xia LH, Guo T, Shen GX, Zhu HH, Zhao T, Song SJ: Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia. Chin Med J (Engl); 2009 Sep 5;122(17):1969-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
  • BACKGROUND: Most patients with acute myelogenous leukemia (AML) suffer from disordered hemostasis.
  • We have previously shown that annexin II (Ann II), a high-affinity co-receptor for plasminogen/tissue plasminogen activator, plays a central role in primary hyperfibrinolysis in patients with acute promyelocytic leukemia (APL).
  • RESULTS: Before As2O3 treatment, Ann II mRNA expression (real-time PCR) was the highest in M3 cells (P < 0.05), higher in M5 cells than that in M1, M2, M4, and M6 cells (P < 0.001), and positively correlated with Ann II protein expression (flow cytometry) (r = 0.752, P < 0.01).
  • Exposure for up to 120 hours to As2O3 (1 micromol/L) had no significant effect on Ann II protein in M1 and M2 leukemic cells, but decreased Ann II protein expression twofold within 48 hours of exposure in M3 cells (P < 0.05) and twofold within 96 hours in M5 cells (P < 0.05).
  • The rate of plasmin generation was higher in APL, M5, and M4 cells than in M1, M2, and M6 cells.
  • Furthermore, As2O3 affects more than one form of AML (APL, M4 and M5), suggesting its potential role in their management.
  • [MeSH-major] Annexin A2 / metabolism. Arsenicals / pharmacology. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Down-Regulation / drug effects. Leukemia, Promyelocytic, Acute / metabolism. Oxides / pharmacology
  • [MeSH-minor] Adult. Cell Survival / drug effects. Cells, Cultured. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781379.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


53. Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de Thé H, Bazarbachi A: Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica; 2007 Jun;92(6):753-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
  • BACKGROUND AND OBJECTIVES: Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia (APL) and potentially for human T-cell leukemia virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (ATL).
  • We, therefore, investigated the contribution of ceramide to the mechanism of action of ATO in APL and ATL.
  • DESIGN AND METHODS: A human APL-derived cell line (NB4), various ATL-derived lines and an HTLV-I-negative malignant T-cell line were cultured and treated with ATO.
  • RESULTS: Treatment of APL and ATL-derived cells with a clinically achievable concentration of ATO induced accumulation of cytotoxic levels of ceramide.
  • The effects of ATO on ceramide levels in APL cells were more potent than those of all-trans retinoic acid (ATRA).
  • Interestingly, the effects of ATO on de novo ceramide synthesis were similar in APL and ATL-derived cells despite the defective pathway in ATL cells.
  • [MeSH-major] Arsenicals / pharmacology. Ceramides / biosynthesis. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Oxides / pharmacology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550847.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Ceramides; 0 / Oxides; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.80 / ceramide glucosyltransferase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


54. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol; 2006 Jan;17(1):131-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
  • INTRODUCTION: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.
  • MATERIALS AND METHODS: We studied 111 patients with APL.
  • Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved.
  • CONCLUSIONS: Arsenic trioxide is effective as first-line treatment for APL.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227315.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


55. Nakamura M, Hamasaki T, Tokitou M, Baba M, Hashimoto Y, Aoyama H: Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis. Bioorg Med Chem; 2009 Jul 1;17(13):4740-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis.
  • Adult T cell leukemia (ATL), caused by infection of human T-lymphotropic virus type 1 (HTLV-1), has a poor prognosis and curative therapy is unavailable, so it is important to find or design superior lead compounds for the drug treatment of ATL.
  • We used our micro-reversed fragment-based drug design hypothesis and multi-template hypothesis to extract the tetrahydrotetramethylnaphthalene (TMN) skeleton from tamibarotene, a useful medicament for the treatment of acute promyelocytic leukemia (APL).
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / chemistry. Tetrahydronaphthalenes / pharmacology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443225.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoids; 0 / Small Molecule Libraries; 0 / Tetrahydronaphthalenes
  •  go-up   go-down


56. Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M: Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Am J Hematol; 2006 May;81(5):349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
  • A crude incidence rate ratio was calculated by ratio of crude incidence rate in our subject to population-based incident rate of all leukemia (ICD: C91-95) in the same region.
  • Three cases of acute promyelocytic leukemia (APL) occurred during gefitinib treatment, and these patients' past treatment histories are presented herein.
  • All presented a normal karyotype with positive PML-RARalpha in RT-PCR, indicating submicroscopic translocation.
  • They responded well to APL treatments, including all-trans-retinoic acid.
  • The crude incident rate ratio was 639.9 (95% confidence interval: 131.6-1,878.9, P < 0.0001) when the APL incidence in this cohort was compared to all leukemia cases in the general population in the same district in Japan.
  • Thus we had three cases of secondary APL patients within the gefitinib-treated NSCLC cohort.
  • Although we cannot exclude an effect of past exposure of other cytotoxic agents and radiotherapy as a cause of APL, APL inducibility of gefitinib should be clarified in the further study.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Leukemia, Promyelocytic, Acute. Lung Neoplasms / drug therapy. Quinazolines / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Incidence. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors


57. Caccavo D, Pellegrino NM, Lorusso F, Capotorto M, Vacca M, Vimercati A, Depalo R: Anticardiolipin antibody levels in women undergoing first in vitro fertilization/embryo transfer. Hum Reprod; 2007 Sep;22(9):2494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The clinical relevance of antiphospholipid antibodies (aPL) in women undergoing in vitro fertilization/embryo transfer (IVF/ET) and the role of IVF treatment in affecting antiphospholipid levels are controversial.
  • [MeSH-minor] Adult. Endometriosis / complications. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Infertility / etiology. Infertility / therapy. Pregnancy. Pregnancy Rate. Prospective Studies. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609246.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


58. Shimizu D, Nomura K, Matsuyama R, Matsumoto Y, Ueda K, Masuda K, Taki T, Nishida K, Horiike S, Kishimoto S, Yanagisawa A, Taniwaki M: Scrotal Ulcers Arising during Treatment with All-trans Retinoic Acid for Acute Promyelocytic Leukemia. Intern Med; 2005 May;44(5):480-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scrotal Ulcers Arising during Treatment with All-trans Retinoic Acid for Acute Promyelocytic Leukemia.
  • All-trans retinoic acid (ATRA) is effective in approximately 90% of the cases of acute promyelocytic leukemia (APL) with a low incidence of adverse effects.
  • We report a patient with APL who developed skin ulcers of the scrotum concomitant with high fever during treatment that included ATRA.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Scrotum. Skin Ulcer / chemically induced. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Marrow / pathology. Follow-Up Studies. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942099.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


59. Burgos PI, McGwin G Jr, Reveille JD, Vilá LM, Alarcón GS: Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford); 2010 Sep;49(9):1720-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the MV model, age [hazard ratio (HR) = 1.06; 95% CI 1.03, 1.08; P < 0.0001], health insurance (HR = 0.53; 95% CI 0.30, 0.94; P = 0.029), smoking (HR = 1.85; 95% CI 1.01, 3.40; P = 0.048), damage (T0) (HR = 1.44; 95% CI 1.20, 1.71; P < 0.0001), aPL (HR = 2.12; 95% CI 1.19, 3.76; P = 0.011) and glucocorticoid (highest dose) (HR = 1.01; 95% CI 1.01, 1.02; P < 0.0001) were significant.
  • CONCLUSIONS: Age, poverty, smoking, damage accrual, aPL and higher doses of glucocorticoids were independently associated with a shorter time to the first thrombotic event; health insurance had a protective effect.

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Rheumatol. 2001 Sep;13(5):345-51 [11604587.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):20-8 [19103632.001]
  • [Cites] J Rheumatol. 2002 Dec;29(12):2531-6 [12465147.001]
  • [Cites] N Engl J Med. 2003 Dec 18;349(25):2399-406 [14681505.001]
  • [Cites] Arthritis Rheum. 2004 Mar;50(3):849-57 [15022327.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2569-79 [15334471.001]
  • [Cites] Arthritis Rheum. 1989 Sep;32(9):1107-18 [2775320.001]
  • [Cites] Am J Med. 1992 Nov;93(5):513-9 [1442853.001]
  • [Cites] J Rheumatol. 1994 Jun;21(6):1067-72 [7932417.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2211-9 [7593607.001]
  • [Cites] Am J Med. 1996 May;100(5):530-6 [8644765.001]
  • [Cites] Lupus. 1996 Jun;5 Suppl 1:S16-22 [8803905.001]
  • [Cites] Am J Epidemiol. 1997 Mar 1;145(5):408-15 [9048514.001]
  • [Cites] Arthritis Rheum. 1997 May;40(5):809-13 [9153540.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] Thromb Haemost. 1998 Mar;79(3):549-53 [9531038.001]
  • [Cites] Arthritis Rheum. 1998 Jul;41(7):1161-72 [9663471.001]
  • [Cites] Arch Intern Med. 1998 Nov 23;158(21):2315-23 [9827782.001]
  • [Cites] Lupus. 1999;8(3):197-209 [10342712.001]
  • [Cites] Rheumatology (Oxford). 2005 Oct;44(10):1303-7 [16030085.001]
  • [Cites] Lupus. 2008 Apr;17(4):281-8 [18413408.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]
  • (PMID = 20498010.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR49084; United States / NCRR NIH HHS / RR / M01-RR02558; United States / NCRR NIH HHS / RR / P20 RR011126; United States / NCRR NIH HHS / RR / M01 RR002558; United States / NCRR NIH HHS / RR / 1P20RR11126; United States / NCRR NIH HHS / RR / M01 RR000032; United States / NIAMS NIH HHS / AR / P01 AR049084; United States / NCRR NIH HHS / RR / M01-RR00032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2948827
  •  go-up   go-down


60. Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F: Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood; 2008 Oct 15;112(8):3383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
  • Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17) translocation is a well-recognized complication of cancer treatment with agents targeting topoisomerase II.
  • Analysis of 12 cases of mitoxantrone-related t-APL in MS patients revealed an altered distribution of chromosome 15 breakpoints versus de novo APL, biased toward disruption within PML intron 6 (11 of 12, 92% vs 622 of 1022, 61%: P = .035).
  • Despite this intron spanning approximately 1 kb, breakpoints in 5 mitoxantrone-treated patients fell within an 8-bp region (1482-9) corresponding to the "hotspot" previously reported in t-APL, complicating mitoxantrone-containing breast cancer therapy.
  • Another shared breakpoint was identified within the approximately 17-kb RARA intron 2 involving 2 t-APL cases arising after mitoxantrone treatment for MS and breast cancer, respectively.
  • Analysis of PML and RARA genomic breakpoints in functional assays in 4 cases, including the shared RARA intron 2 breakpoint at 14 446-49, confirmed each to be preferential sites of topoisomerase IIalpha-mediated DNA cleavage in the presence of mitoxantrone.
  • This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Dec;20(12):2217-8 [17051242.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1943-9 [16990778.001]
  • [Cites] Biochemistry. 2007 May 22;46(20):6097-108 [17458941.001]
  • [Cites] Chem Res Toxicol. 2008 Apr;21(4):936-43 [18293940.001]
  • [Cites] Neurology. 2008 Aug 5;71(6):457-8 [18678830.001]
  • [Cites] Mult Scler. 2002 Oct;8(5):441-5 [12356214.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2000;64:221-53 [10697411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4790-5 [10758153.001]
  • [Cites] Biochemistry. 2001 Feb 6;40(5):1159-70 [11170441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9802-7 [11493704.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1972-6 [12200354.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):954-5 [12297591.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):175-88 [12508246.001]
  • [Cites] Mult Scler. 2003 Mar;9(2):213-4 [12708818.001]
  • [Cites] Leukemia. 2003 May;17(5):985-6 [12750718.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Mult Scler. 2003 Aug;9(4):426 [12926850.001]
  • [Cites] Methods Mol Med. 2004;91:151-73 [14573936.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8448-59 [14627986.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1332-8 [14638950.001]
  • [Cites] Mult Scler. 2004 Feb;10(1):92 [14760961.001]
  • [Cites] J Neurol. 2004 Jun;251(6):762-3 [15311359.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1561-2 [15215874.001]
  • [Cites] Mult Scler. 2004 Aug;10(4):472-4 [15327049.001]
  • [Cites] J Biol Chem. 1989 Mar 15;264(8):4412-6 [2538443.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1913-20 [7829529.001]
  • [Cites] Leukemia. 1996 Jan;10(1):27-31 [8558933.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1296-302 [8709634.001]
  • [Cites] Curr Opin Oncol. 1996 Jan;8(1):3-12 [8868093.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):581-90 [8932918.001]
  • [Cites] J Neurol. 1997 Mar;244(3):153-9 [9050955.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1786-95 [9164186.001]
  • [Cites] Biochemistry. 1997 May 20;36(20):5934-9 [9166762.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] Leukemia. 1998 Mar;12(3):441-2 [9529141.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] N Engl J Med. 2005 Apr 14;352(15):1529-38 [15829534.001]
  • [Cites] Arq Neuropsiquiatr. 2005 Jun;63(2A):327-9 [16100984.001]
  • [Cites] Clin Ther. 2006 Apr;28(4):461-74 [16750460.001]
  • [Cites] J Miss State Med Assoc. 2007 Jul;48(7):206-7 [17939254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9 [17578914.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108 [16857431.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Apr 15;182(2):126-9 [18406875.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1282-97 [16893685.001]
  • [Cites] Biochimie. 2007 Apr;89(4):508-15 [17397986.001]
  • (PMID = 18650449.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077683; United States / NIGMS NIH HHS / GM / R01 GM033944; United States / NIGMS NIH HHS / GM / GM33944; United States / NCI NIH HHS / CA / R01CA077683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 9007-49-2 / DNA; BZ114NVM5P / Mitoxantrone; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2954750
  •  go-up   go-down


61. Galrão L, Brites C, Atta ML, Atta A, Lima I, Gonzalez F, Magalhães F, Santiago M: Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol; 2007 Nov;26(11):1825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid (aPL) antibodies classically have been associated with thrombotic phenomena and abortion in patients with autoimmune diseases.
  • Using a transversal study, a population of patients diagnosed with HIV, identified through an enzyme-linked immunosorbent assay (ELISA) test and confirmed by Western blotting, aged above 17 years old, was investigated.
  • Of the 90 patients, 40 (44.4%) were reactive for at least one type of aPL antibody (aCL and/or anti-beta2 GPI).
  • The frequency of aCL was 17.8%, from which 15 (16.7%) had aCL IgG, 3 (3.3%) IgM, and 1 (1.1%) IgA.
  • No association was observed between immunoreactivity for aPL antibodies in general or each isotype in particular and the presence of APS manifestation.
  • In the present study, it was possible to observe a relatively high frequency of aPL antibodies, particularly for isotype IgA anti-beta2 GPI in HIV.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Blotting, Western. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin G / chemistry. Immunoglobulin M / chemistry. Male. Reagent Kits, Diagnostic. Surveys and Questionnaires. Treatment Outcome


62. Casorelli I, Tenedini E, Tagliafico E, Blasi MF, Giuliani A, Crescenzi M, Pelosi E, Testa U, Peschle C, Mele L, Diverio D, Breccia M, Lo-Coco F, Ferrari S, Bignami M: Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. Leukemia; 2006 Nov;20(11):1978-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute promyelocytic leukemia (APL) is a clonal expansion of hematopoietic precursors blocked at the promyelocytic stage.
  • Gene expression profiles of APL cells obtained from 16 patients were compared to eight samples of CD34+-derived normal promyelocytes.
  • The strong upregulation in APL of some transcripts (FLT3, CD33, CD44 and HGF) was also confirmed at protein level.
  • Interestingly, a trend toward a transcriptional repression of genes involved in different DNA repair pathways was found in APL and confirmed by real-time polymerase chain reactor (PCR) in a new set of nine APLs.
  • To investigate the expression pathways underlying the development of APL occurring as a second malignancy (sAPL), we included in our study eight cases of sAPL.
  • Although both secondary and de novo APL were characterized by a strong homogeneity in expression profiling, we identified a small set of differentially expressed genes that discriminate sAPL from de novo cases.
  • [MeSH-major] DNA Repair / genetics. Granulocyte Precursor Cells / pathology. Granulocyte Precursor Cells / physiology. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Antigens, CD44 / genetics. Antigens, CD44 / metabolism. Antigens, Differentiation, Myelomonocytic / genetics. Antigens, Differentiation, Myelomonocytic / metabolism. Cluster Analysis. Female. Flow Cytometry. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Sialic Acid Binding Ig-like Lectin 3. Transcription, Genetic. fms-Like Tyrosine Kinase 3 / genetics. fms-Like Tyrosine Kinase 3 / metabolism


63. Tennent-Brown BS, Wilkins PA, Lindborg S, Russell G, Boston RC: Assessment of a point-of-care lactate monitor in emergency admissions of adult horses to a referral hospital. J Vet Intern Med; 2007 Sep-Oct;21(5):1090-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of a point-of-care lactate monitor in emergency admissions of adult horses to a referral hospital.
  • ANIMALS: The study included adult horses presented for emergency evaluation.
  • [LAC] was measured with whole blood (AWB) and plasma (APL) by means of a POC monitor (Accutrend) and compared with results from whole blood measured by a laboratory blood gas analyzer (NOVA).
  • Agreement (p +/- SE) was closest between APL and NOVA (0.97 +/- 0.01); an average observed difference of 0.15 +/- 0.89 (mean +/- SD) and 95% limits of agreement (LOA) -1.89, 1.59 also were found.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939569.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid
  •  go-up   go-down


64. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E: Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus; 2007;16(5):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of the total 362 SLE patients in our service, 223 patients had antiphospholipid antibodies (aPL), of whom 110 met the criteria of antiphospholipid syndrome.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged


65. Pascual-Leone A, Greenberg LS: Emotional processing in experiential therapy: why "the only way out is through.". J Consult Clin Psychol; 2007 Dec;75(6):875-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Anger. Fear. Female. Grief. Humans. Male. Middle Aged. Self Efficacy

  • MedlinePlus Health Information. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (copyright) 2007 APA.
  • (PMID = 18085905.001).
  • [ISSN] 0022-006X
  • [Journal-full-title] Journal of consulting and clinical psychology
  • [ISO-abbreviation] J Consult Clin Psychol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. López-Pedrera C, Buendía P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M, Velasco F: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum; 2006 Jan;54(1):301-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Antiphospholipid syndrome (APS) is characterized by thrombosis and the presence of antiphospholipid antibodies (aPL).
  • However, the intracellular mechanisms involved in aPL-mediated up-regulation of TF on monocytic cells are not understood.
  • This study was undertaken to investigate the intracellular signals induced by aPL that mediate TF activation in monocytes from APS patients.
  • METHODS: We analyzed, both in vivo and in vitro, aPL interactions with proteins that have signaling functions, including mitogen-activated protein kinases (MAP kinases) and NF-kappaB/Rel proteins.
  • Treatment of normal monocytes with aPL activated ERK-1 and p38 MAP kinases, as well as the IkappaB/NF-kappaB pathway, in a dose-dependent manner.
  • NF-kappaB activation and IkappaBalpha degradation induced by aPL were inhibited by the NF-kappaB inhibitor SN50 and the p38 MAP kinase inhibitor SB203580, thus suggesting crosstalk between these pathways.
  • However, the MEK-1/ERK inhibitor PD98059 did not affect aPL-induced NF-kappaB binding activity.
  • TF expression induced by aPL was significantly inhibited by combined treatment with the 3 inhibitors.
  • CONCLUSION: Our results suggest that aPL induces TF expression in monocytes from APS patients by activating, simultaneously and independently, the phosphorylation of MEK-1/ERK proteins, and the p38 MAP kinase-dependent nuclear translocation and activation of NF-kappaB/Rel proteins.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Phosphorylation. Protein Transport


67. Matsubayashi H, Sugi T, Arai T, Shida M, Kondo A, Suzuki T, Izumi S, McIntyre JA: IgG-antiphospholipid antibodies in follicular fluid of IVF-ET patients are related to low fertilization rate of their oocytes. Am J Reprod Immunol; 2006 May;55(5):341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: Patients undergoing in vitro fertilization and embryo transfer (IVF-ET) failures show an increased incidence of antiphospholipid antibodies (aPL) in their blood.
  • The physiological manifestations of aPL in this patient group are nonetheless controversial.
  • Pathological effects of aPL on embryos in vitro have been documented.
  • We questioned whether aPL if found in follicular fluids (FFs) could result in embryonic damage.
  • METHOD OF STUDY: Blood from 44 patients with three or more IVF-ET failures were tested by enzyme-linked immunosorbent assays (ELISA) for the presence of immunoglobulin (Ig)G, IgM and IgA aPL.
  • Both the 29 aPL-positive and 15 aPL-negative patients gave permission for FF collection during their next IVF-ET attempt for additional aPL determinations.
  • RESULTS: Patients with no aPL in their blood, had no aPL in their FFs.
  • Patients with IgG and/or IgM aPL in their blood had IgG but not IgM in their respective FFs.
  • CONCLUSIONS: The presence of IgG aPL in FFs and increased infertility length were significantly related to lower fertilization rates, independently.
  • Follicular fluid IgG aPL appears as a risk factor in association with successful IVF-ET outcomes.
  • [MeSH-minor] Adult. Embryo Transfer. Female. Humans. Immunoglobulin G / metabolism. Immunoglobulin M / metabolism. Infertility, Female / immunology. Infertility, Female / therapy. Middle Aged. Oocytes / immunology. Risk Factors. Treatment Failure

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Reprod Immunol. 2007 Mar;57(3):232
  • (PMID = 16635208.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


68. Chen Y, Gu L, Zhou C, Wu X, Gao J, Li Q, Zhu Y, Jia C, Ma Z: Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival. Int J Hematol; 2010 May;91(4):708-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
  • The t(5;17)/NPM-RARalpha is the second variant chromosomal translocation in acute promyelocytic leukemia (APL) to be characterized and also the second most plentiful variant translocation.
  • So far, there is a lack of information on the effectiveness of arsenic trioxide (ATO) in relapsed APL with variant RARalpha chimera including t(5;17)/NPM-RARalpha.
  • We report here a long-term survived APL patient with variant NPM-RARalpha fusion who relapsed four times and each time responded well to ATO or ATO-based re-induction therapy.
  • This case illustrates the long-term efficiency and safety of ATO-based therapy not only in newly diagnosed APL, but also in relapsed APL including those with variant translocations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Dec 1;110(12 ):4073-6 [17712046.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1113-8 [10023688.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):430-3 [18683144.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):387-408 [12935958.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Int J Hematol. 2007 Oct;86(3):246-9 [17988991.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]
  • [Cites] Am J Hematol. 2002 Aug;70(4):292-9 [12210810.001]
  • (PMID = 20405253.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / NPM-RARalpha protein, human; 0 / Oncogene Proteins, Fusion; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


69. Yang YM, Liu T: [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):965-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A].
  • The acute promyelocytic leukemia (APL) with DIC was diagnosed.
  • The tanshinone II A could induce CR of APL with ATRA resistance, no side effect was observed; there is a reoccurring possibility from consolidation therapy with tanshinone II A.
  • [MeSH-major] Drug Resistance, Neoplasm. Leukemia, Promyelocytic, Acute / drug therapy. Phenanthrenes / therapeutic use. Remission Induction / methods. Tretinoin / pharmacology
  • [MeSH-minor] Adult. Diterpenes, Abietane. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236602.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Diterpenes, Abietane; 0 / Phenanthrenes; 03UUH3J385 / tanshinone; 5688UTC01R / Tretinoin
  •  go-up   go-down


70. Wang T, Qiu JY, Yu CF, Ma XL, Jia XP, Wang YP, Liu HX, Lin YH, Tong CR, Lu DP: [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):537-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization].
  • To investigate the biological characteristics of the variant translocation der ins (17;15) in a patient with acute promyelocytic leukemia (APL), the conventional G-banding technique, interphase fluorescence in situ hybridization (int-FISH), RT-PCR, gene scanning, gene sequence and flow cytometry were performed.
  • The results indicated that the variant translocation der ins (17, 15) observed by G banding technique was a rare type, the int-FISH assay by using dual-color pml/raralpha fusion probes confirmed the cytogenetic findings.
  • The detection results of other molecular methods demonstrated the existence of the whole pml/raralpha fusion gene, while this case had insertion variant translocation.
  • In conclusion, the variant translocation der ins (17;.
  • 15) is rare type in APL, its incidence is lower, several signal types in detection of int-FISH were observed and the combination chemotherapy for this patient showed more obvious efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549359.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Bhatt SP, Handa R, Gulati GS, Sharma S, Pandey RM, Aggarwal P, Ramakrishnan L, Shankar S: Peripheral vascular disease in systemic lupus erythematosus. Lupus; 2007;16(9):720-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen (28%) patients had PVD, of whom three had positive markers for antiphospholipid antibody (aPL) and six were asymptomatic.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Antiphospholipid / metabolism. Cross-Sectional Studies. Dyslipidemias / complications. Female. Humans. Hypertension / complications. Male. Middle Aged. Prospective Studies. Raynaud Disease / complications. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728365.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


72. Di Simone N, Marana R, Castellani R, Di Nicuolo F, D'Alessio MC, Raschi E, Borghi MO, Chen PP, Sanguinetti M, Caruso A, Meroni PL: Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum; 2010 May;62(5):1504-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to investigate whether abnormal HB-EGF expression plays a pathogenic role in antiphospholipid antibody (aPL)-mediated defective placentation.
  • Polyclonal IgG fractions or monoclonal beta(2)-glycoprotein I-dependent aPL and their respective controls were investigated for the following 4 features: their binding to human trophoblast monolayers, as determined by cell enzyme-linked immunosorbent assay (ELISA); their effect on HB-EGF expression by Western blotting in trophoblast cell extracts as well as by ELISA as a protein secreted in the culture supernatants; their inhibitory effect on in vitro trophoblast invasiveness, as evaluated by Matrigel assay; and their inhibitory effect on matrix metalloproteinase (MMP) levels, as measured by gelatin zymography.
  • Polyclonal and monoclonal aPL bound to trophoblast monolayers and significantly reduced the in vitro synthesis and secretion of HB-EGF.
  • Heparin inhibited aPL binding and restored HB-EGF expression in a dose-dependent manner.
  • Addition of recombinant HB-EGF reduced the in vitro aPL-induced inhibition of Matrigel invasiveness as well as MMP-2 levels.
  • CONCLUSION: These preliminary findings suggest that the reduction of aPL-mediated HB-EGF represents an additional mechanism that is responsible for the defective placentation associated with APS and that heparin protects from aPL-induced damage by inhibiting antibody binding.
  • [MeSH-minor] Adult. Antibodies, Antiphospholipid / immunology. Antibodies, Antiphospholipid / pharmacology. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Anticoagulants / pharmacology. Blotting, Western. Cells, Cultured. Down-Regulation / immunology. Female. Gene Expression / immunology. Heparin, Low-Molecular-Weight / pharmacology. Heparin-binding EGF-like Growth Factor. Humans. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Pilot Projects. Pregnancy. RNA, Messenger / metabolism. Trophoblasts / cytology. Trophoblasts / drug effects. Trophoblasts / immunology. beta 2-Glycoprotein I / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131286.001).
  • [ISSN] 1529-0131
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antibodies, Monoclonal; 0 / Anticoagulants; 0 / HBEGF protein, human; 0 / Heparin, Low-Molecular-Weight; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / beta 2-Glycoprotein I; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


73. Belvís R, Santamaría A, Martí-Fàbregas J, Cocho D, Borrell M, Fontcuberta J, Martí-Vilalta JL: Diagnostic yield of prothrombotic state studies in cryptogenic stroke. Acta Neurol Scand; 2006 Oct;114(4):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PS included plasmatic determinations of antiphospholipid (APL) antibodies and lupus anticoagulant (LA), S (SPd) and C (CPd) protein deficiencies, and genetic analysis of the prothrombin gene mutation (PT G20210A) and the factor V Leiden mutation (FV G1691A).
  • RESULTS: From a total of 89 patients (mean age 56.9 +/- 14.3 years, 53% men), we identified 16 PS in 15 patients (16.85%): APL-6, LA-2, SPd-2, CPd-1, PT G20210A -3 and FV G1691A -2.
  • One patient presented an association (APL and PT G20210A).
  • [MeSH-minor] Adult. Age Distribution. Aged. Antibodies, Antiphospholipid / blood. Blood Coagulation / genetics. Cardiovascular Diseases / complications. Cardiovascular Diseases / genetics. Factor V / genetics. Female. Humans. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Prospective Studies. Protein C / metabolism. Protein S / metabolism. Prothrombin / genetics. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16942544.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lupus Coagulation Inhibitor; 0 / Protein C; 0 / Protein S; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin
  •  go-up   go-down


74. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol; 2009 Aug 01;27(22):3650-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
  • PURPOSE: Molecular diagnostics and early assessment of treatment response that use methodologies capable of detecting submicroscopic disease can distinguish subgroups of patients with leukemia at differing relapse risk.
  • METHODS: Real-time quantitative polymerase chain reaction (RQ-PCR) assays to detect leukemia-specific transcripts (ie, PML-RARA, RARA-PML) were used to prospectively analyze 6,727 serial blood and marrow samples from 406 patients with newly diagnosed acute promyelocytic leukemia (APL) who were receiving all-trans-retinoic acid and anthracycline-based chemotherapy.
  • RESULTS: MRD monitoring according to the recommended schedule successfully identified the majority of patients subject to relapse and provided the most powerful predictor of relapse-free survival (RFS) in multivariable analysis (hazard ratio, 17.87; 95% CI, 6.88 to 46.41; P < .0001); MRD monitoring was far superior to presenting WBC (hazard ratio, 1.02; 95% CI, 1.00 to 1.03; P = .02), which is currently widely used to guide therapy.
  • CONCLUSION: Rigorous sequential RQ-PCR monitoring provides the strongest predictor of RFS in APL and, when coupled with pre-emptive therapy, provides a valid strategy to reduce rates of clinical relapse.
  • This provides a model for development of a more individualized approach to management of other molecularly defined subtypes of acute leukemia.
  • [MeSH-major] Arsenicals / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Neoplasm Recurrence, Local / diagnosis. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Oxides / administration & dosage
  • [MeSH-minor] Adult. Aged. Blood Chemical Analysis. Bone Marrow / pathology. Cohort Studies. Confidence Intervals. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Monitoring, Physiologic / methods. Multivariate Analysis. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Severity of Illness Index. Survival Analysis. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):e62; author reply e63-4 [19841316.001]
  • (PMID = 19506161.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133; United Kingdom / Medical Research Council / / G9800001
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


75. Miesbach W, Gökpinar B, Gilzinger A, Claus D, Scharrer I: Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Immunobiology; 2005;210(10):755-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with antiphospholipid antibodies (aPL) are at increased risk of recurrent thromboembolic events, but the possibility of predicting this risk seems rather limited.
  • Similarities were recently found between aPL and CRP in the pathology of thrombosis.
  • A follow-up investigation was done in a cohort of 55 aPL-positive patients with acute manifestations of neurological disease. hs-CRP levels were measured in all patients at enrollment and were compared to the patients' condition after a median period of 32 months.
  • In patients with aPL, elevated levels of hs-CRP were closely associated with an increased rate of recurrent or residual symptoms (OR, 12.5; 95% CI, 3.72-41.94) and were not related to other risk factors, except smoking (p<0.05).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / immunology. Cohort Studies. Female. Humans. Lupus Coagulation Inhibitor / immunology. Male. Middle Aged. Prognosis. Risk Factors


76. Salomoni P: Stemming out of a new PML era? Cell Death Differ; 2009 Aug;16(8):1083-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stemming out of a new PML era?
  • The promyelocytic leukaemia protein PML is a growth and tumour suppressor inactivated in acute promyelocytic leukaemia (APL).
  • Recent evidence indicates that PML plays a tumour-suppressive role in cancer of multiple histological origins.
  • However, it is only very recently that PML growth-suppressive functions have been implicated in regulating physiological processes and tissue homoeostasis.
  • In particular, it has been shown that PML is one of the key cell-cycle regulators controlling stem cell function in multiple tissues, from the blood to the brain.
  • As a consequence, PML loss has an impact on tissue development and maintenance of stem cell pools.
  • In addition, new data suggest that PML regulates self-renewal in cancer stem cells.
  • Finally, the oncogenic fusion protein PML/RARalpha, contrary to the conventional view, appears to hijack growth-suppressive pathways to promote transformation of haematopoietic stem cells and to maintain the APL stem cell niche.
  • Overall, these findings not only represent a change in paradigm in the field of PML/APL research, but also contribute to the understanding of fundamental mechanisms underlying stem cell function in vivo.
  • The main objective of this review is to critically discuss the very recent literature on the role of PML in stem cells and tumour-initiating cells.
  • [MeSH-minor] Adult Stem Cells / cytology. Animals. Antigen-Presenting Cells / cytology. Cell Cycle. Cell Differentiation. Humans. Mammary Glands, Human / cytology. Mice

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521423.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Pml protein, mouse; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 95
  •  go-up   go-down


77. Asano Y, Sarukawa M, Idezuki T, Harada S, Kaji K, Nakasu I, Igarashi A: Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clin Rheumatol; 2006 Jul;25(4):585-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiphospholipid antibodies (aPL) have been reported to occur in several conditions other than antiphospholipid syndrome, including infections.
  • We herein report the case of a 21-year-old Japanese woman with Parvovirus B19 infection, who developed multiple pulmonary emboli associated with aPL, a lupus anticoagulant and IgM anticardiolipin antibody.
  • Considering the high prevalence of Parvovirus B19 infection, we should be aware of thrombosis associated with transient aPL antibodies in this infectious disease.
  • [MeSH-minor] Adult. Antibodies, Viral / blood. Anticoagulants / therapeutic use. Female. Humans. Warfarin / therapeutic use

  • Genetic Alliance. consumer health - Human parvovirus B19 infection.
  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2000 Oct 15;109(6):512-3 [11184773.001]
  • [Cites] J Rheumatol. 1998 Feb;25(2):200-2 [9489806.001]
  • [Cites] J Gastroenterol. 2000;35(4):272-7 [10777156.001]
  • [Cites] J Rheumatol. 1995 Oct;22(10):1899-906 [8991989.001]
  • [Cites] Semin Arthritis Rheum. 2002 Feb;31(4):256-63 [11836658.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):241-4 [10702499.001]
  • [Cites] Prenat Diagn. 1995 Dec;15(12):1109-13 [8750289.001]
  • [Cites] Thromb Haemost. 1992 Sep 7;68(3):297-300 [1440495.001]
  • [Cites] Autoimmun Rev. 2003 Jun;2(4):218-23 [12848949.001]
  • [Cites] Lupus. 1997;6(5):455-61 [9229365.001]
  • (PMID = 16421644.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antibodies, Viral; 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


78. Terashi H, Uchiyama S, Hashimoto S, Miyazaki K, Tsutsumi Y, Yamazaki M, Iwata M: Clinical characteristics of stroke patients with antiphospholipid antibodies. Cerebrovasc Dis; 2005;19(6):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed differences in clinical characteristics between 40 antiphospholipid-antibody (aPL)-positive and 40 aPL-negative stroke patients.
  • RESULTS: Stroke patients with aPL were significantly younger and were more likely to be women in comparison with stroke patients without aPL.
  • Valvular heart disease, neurological complications and hematological disorders were more frequent in the aPL-positive group.
  • The mean value of thrombin-antithrombin III complex was significantly lower in the aPL-positive group.
  • Cerebral infarctions in the carotid system were less and large-artery lesions more frequent in the aPL-positive patients.
  • CONCLUSIONS: Stroke patients with aPL have clinical characteristics distinct from stroke patients without aPL.
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Aged. Antibodies, Anticardiolipin / analysis. Biomarkers. Female. Heart Diseases / complications. Heart Diseases / epidemiology. Humans. Hypertension / complications. Hypertension / epidemiology. Lupus Coagulation Inhibitor / analysis. Male. Middle Aged. Nervous System Diseases / epidemiology. Nervous System Diseases / etiology. Retrospective Studies. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15863981.001).
  • [ISSN] 1015-9770
  • [Journal-full-title] Cerebrovascular diseases (Basel, Switzerland)
  • [ISO-abbreviation] Cerebrovasc. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Biomarkers; 0 / Lupus Coagulation Inhibitor
  •  go-up   go-down


79. Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM: Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. J Rheumatol; 2008 Sep;35(9):1768-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We have observed several cases of patients with systemic lupus erythematosus (SLE) who developed antiphospholipid antibodies (aPL) or full blown antiphospholipid syndrome (APS) after being successfully treated with cyclophosphamide (CYC).
  • The disease activity over time was evaluated using the European Consensus Lupus Activity Measurement (ECLAM) scoring system, as well as initial and cumulative anti-dsDNA antibody titers and C3, C4 complement levels. aPL titers (IgG and IgM) were documented for all patients.
  • Seroconversion was defined as the de novo appearance of aPL antibodies at a titer higher than the 99th percentile of 100 normal sera, tested on 2 occasions 12 weeks apart.
  • CONCLUSION: Our data suggest that CYC therapy might be associated with upregulation of aPL and development of antiphospholipid syndrome despite suppression of SLE activity.
  • [MeSH-minor] Adult. Antiphospholipid Syndrome / immunology. Female. Humans. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Young Adult


80. Ma XJ, Ren HY, Cen XN, Qiu ZX, Wang WS, Ou JP, Wang Y, Xu WL, Li Y, Wang MJ, Wang LH, Dong YJ, Yin Y, Liang ZY: [Efficacy analysis of sequential treatment with chemotherapy, ATRA and As(2)O(3) for acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2010 May;31(5):328-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy analysis of sequential treatment with chemotherapy, ATRA and As(2)O(3) for acute promyelocytic leukemia].
  • OBJECTIVE: To investigate the efficacy and treatment outcome of different induction regimens, and different post-remission therapies for adult acute promyelocytic leukemia (APL).
  • METHODS: The outcome of 73 patients with newly diagnosed APL were retrospectively analyzed.
  • The median TTC in ATRA with As(2)O(3) combination group was 26 (13 - 40) days being the shortest among the three groups. (2) For the post-remission treatment, 3-year OS rates in group I and group II were (95.7 ± 4.3)% and (68.6 ± 11.2)% (P < 0.05), and 3-year DFS rates were (79.0 ± 9.5)%, and (32.9 ± 15.5)%, respectively (P < 0.01).
  • CONCLUSIONS: For adult APL induction with ATRA and As(2)O(3) combination can obtain a higher CR rate, and shorter TTC.
  • The ATRA and As(2)O(3) combination induction with the sequential post-remission therapy is the best strategy for APL treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Leukemia, Promyelocytic, Acute

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122313.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


81. Xiang Y, Wang XB, Sun SJ, Guo AX, Wei AH, Cheng YB, Huang SL: [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jul;30(7):440-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia].
  • OBJECTIVE: To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).
  • There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTc interval in 110 APL patients observed before and after the treatment.
  • CONCLUSION: CHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Phytotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Plant Preparations / adverse effects. Plant Preparations / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954593.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


82. Huang HB, Wu SQ, Zhan R, Fan LP: [april mRNA expression in newly diagnosed leukemia patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1414-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [april mRNA expression in newly diagnosed leukemia patients].
  • This study was aimed to quantitatively detect the levels of april mRNA expression in leukemia patients so as to provide theoretical basis for the target therapy directing at april in leukemia.
  • Real time fluorescent quantitative PCR was used to detect the relative expression level of april mRNA in newly diagnosed leukemia patients and to analyze the changes of its expression level in various type of leukemia.
  • The results showed that the april mRNA expression level in acute leukemia (AL) patients was significantly higher than that in normal controls, there was statistical difference between them (p < 0.05); april mRNA expression level in acute myeloid leukemia (AML) patients was significantly higher than that in normal controls (p < 0.05) and positively correlated with white blood cell count ≥ 20.0 × 10(9)/L (p < 0.05), but not related with extramedullary infiltration and the expression of CD34.
  • Except for acute promyelocytic leukemia (APL), april mRNA expression level was negatively correlated with sensitivity of patients to chemotherapy. april mRNA expression levels in acute lymphoid leukemia (ALL) and chronic myeloid leukemia (CML) patients were not higher than that in normal controls, there was no statistical difference between them (p > 0.05).

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176341.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / TNFSF13 protein, human; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


83. Chen SJ, Chen LJ, Zhou GB: [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb;13(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last twenty years, using all-trans retinoic acid (ATRA) as a differentiation inducer, Shanghai Institute of Hematology has achieved an important breakthrough in the treatment of acute promyelocytic leukemia (APL), which realized the theory of reversing phenotype of cells and provided a successful model of differentiation therapy in cancers.
  • Our group first discovered in the world the variant chromosome translocation t(11;17)(q23;q21) of APL, and cloned the PML-RAR alpha, PLZF-RAR alpha and NPM-RAR alpha fusion genes corresponding to the characterized chromosome translocations t(15;17); t(11;17) and t(5;17) in APL.
  • Moreover, establishment of transgenic mice model of APL proved their effects on leukemogenesis.
  • The ability of ATRA to modify the recruitment of nuclear receptor co-repressor with PML-RAR alpha but not PLZF-RAR alpha caused by the variant chromosome translocation elucidated the therapeutic mechanism of ATRA from the molecular level and provides new insight into transcription-modulating therapy.
  • Since 1994, our group has successfully applied arsenic trioxide (As(2)O(3)) in treating relapsed APL patients, with the complete remission rate of 70% - 80%.
  • The molecular mechanism study revealed that As(2)O(3) exerts a dose-dependent dual effect on APL.
  • Low-dose As(2)O(3) induced partial differentiation of APL cells, while the higher dose induced apoptosis.
  • As(2)O(3) binds ubiquitin like SUMO-1 through the lysine 160 of PML, resulting in the degradation of PML-RAR alpha.
  • Taken together, ATRA and As(2)O(3) target the transcription factor PML-RAR alpha, the former by retinoic acid receptor and the latter by PML sumolization, both induce PML-RAR alpha degradation and APL cells differentiation and apoptosis.
  • Clinical trial in newly diagnosed APL patients showed that ATRA/As(2)O(3) in combination yields a longer disease-free survival time.
  • This is the best clinical effect achieved in treating adult acute leukemia to this day, possibly making APL the first adult curable leukemia.
  • Based on the great success of the pathogenetic gene target therapy in APL, this strategy may extend to other leukemias.
  • Combination of Gleevec and arsenic agents in treating chronic myeloid leukemia has already make a figure both in clinical and laboratory research, aiming at counteracting the abnormal tyrosine kinase activity of ABL and the degradating BCR-ABL fusion protein.
  • In acute myeloid leukemia M(2b), using new target therapy degradating AML1-ETO fusion protein and reducing the abnormal tyrosine kinase activity of c-kit will also lead to new therapeutic management in acute leukemias.

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748426.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Receptors, Retinoic Acid; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


84. Perricone C, De Carolis C, Giacomelli R, Zaccari G, Cipriani P, Bizzi E, Perricone R: High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology (Oxford); 2007 Oct;46(10):1574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Role of anti-phospholipid antibodies (aPL) in recurrent spontaneous abortion (RSA) remains uncertain, while natural killer (NK)-cells are involved in RSA pathogenesis.
  • In this study, patients affected with APS without RSA, APS with RSA and RSA without aPL were studied for NK-cell subpopulation to evaluate its role in abortive events typical of APS.
  • NK-cells levels were evaluated also in RSA without aPL associated with either endocrine (n = 86), anatomic (n = 30) or idiopathic (n = 77) conditions and in 42 healthy women.
  • NK-cells might precipitate damage initiated by aPL or they might cause pathology in RSA independent of aPL.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Immunophenotyping. Lymphocyte Count. Pregnancy

  • Genetic Alliance. consumer health - Recurrent spontaneous abortion.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rheumatology (Oxford). 2007 Oct;46(10):1517-9 [17804454.001]
  • (PMID = 17704519.001).
  • [ISSN] 1462-0324
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Descloux E, Durieu I, Cochat P, Vital Durand D, Ninet J, Fabien N, Cimaz R: Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford); 2008 Feb;47(2):183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of our study was to investigate the prognostic impact of aPL in paediatric onset systemic lupus erythematosus (p-SLE).
  • Chi2-test, Fisher's exact test, incidence rate ratio and Kaplan-Meier survival curves were used to compare aPL-positive and aPL-negative patients considering the value of SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for SLE) at the end of follow-up, the occurrence of thromboses, organ system involvements and need for immunosuppressive treatment in addition to corticosteroids.
  • These aPL were frequently transient or intermittent (10 and 15 cases, respectively), and only rarely persistent over time (five cases).
  • The risk of thrombosis was significantly higher (odds ratio = 6.42) and occurred earlier in the presence of aPL, especially if aPL were persistent (P < 0.05).
  • The association between aPL and neurological, renal, haematological manifestations or need for immunosuppressive treatment was not statistically significant.
  • The risk of damage (SDI > or = 1) in aPL-positive patients was three times higher than in aPL-negative patients (P < 0.05).
  • Four of the six fatal cases occurred in the aPL-positive group.
  • CONCLUSIONS: The presence of aPL in p-SLE could represent not only a risk factor for thrombosis but also a poor prognostic factor overall.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Immunoglobulin M / immunology. Infant. Male. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160418.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Immunoglobulin M
  •  go-up   go-down


91. Vidal M, Corbin V, Chanet V, Ruivard M, Gourdon F, Laurichesse H, Beytout J, Lesens O: [Infections associated to severe thrombotic events and antiphospholipid antibodies]. Med Mal Infect; 2005 Nov;35(11):552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present 2 cases of infections in which the presence of antiphospholipid antibodies (APL), anticardiolipin and anti-beta2-GP1, was associated to the occurrence of significant thrombotic events:.
  • [MeSH-minor] Adult. Humans. Male. Middle Aged. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253461.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  •  go-up   go-down


92. Palomo I, Pereira J, Alarcón M, Vásquez M, Pinochet C, Poblete F, Mendez E, Sandoval J, Vidal R, Pierangeli S: Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients. Clin Rheumatol; 2007 Mar;26(3):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of aPL or anti-beta (2)GPI in the patients was detected by ELISA.
  • These polymorphisms did not correlate with aPL or anti-beta (2)GPI but significant differences were observed with venous thrombosis (p=<0.0001) and arterial thrombosis (p=0.026).
  • [MeSH-minor] Adult. Antibodies, Antiphospholipid / blood. Chile. Female. Humans. Male. Middle Aged. Odds Ratio

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stroke.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1997 Jul;100(1):57-62 [9225969.001]
  • [Cites] Clin Rheumatol. 2004 Apr;23(2):129-33 [15045627.001]
  • [Cites] Hum Genet. 1999 Jul-Aug;105(1-2):63-71 [10480357.001]
  • [Cites] Biochemistry. 1992 Apr 14;31(14):3611-7 [1567819.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):471-4 [12571857.001]
  • [Cites] J Lab Clin Med. 2002 Nov;140(5):336-41 [12434135.001]
  • [Cites] Hum Genet. 1995 Apr;95(4):385-8 [7705832.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):457-62 [7507506.001]
  • [Cites] Lancet. 1990 Jun 30;335(8705):1544-7 [1972485.001]
  • [Cites] Electrophoresis. 1988 Jul;9(7):317-22 [3148463.001]
  • [Cites] Eur J Biochem. 1999 Jan;259(1-2):435-40 [9914524.001]
  • [Cites] Cytogenet Cell Genet. 1992;60(1):31-3 [1582254.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1655-61 [10446865.001]
  • [Cites] Blood. 1985 Nov;66(5):1086-91 [4052628.001]
  • [Cites] Biochemistry. 1991 Dec 17;30(50):11687-94 [1751487.001]
  • [Cites] Lupus. 1999;8(9):742-50 [10602447.001]
  • [Cites] Lancet. 1990 Jul 21;336(8708):177-8 [1973491.001]
  • [Cites] Hum Genet. 1993 May;91(4):401-2 [8099061.001]
  • [Cites] Nucleic Acids Res. 1991 Oct 11;19(19):5444 [1681511.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1066-72 [12648080.001]
  • [Cites] Lancet. 1990 Oct 13;336(8720):952-3 [1976970.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1189-93 [10366111.001]
  • [Cites] J Clin Lab Anal. 2003;17(6):209-15 [14614742.001]
  • [Cites] Biochem J. 1990 May 15;268(1):187-93 [1971508.001]
  • [Cites] Int J Biochem. 1980;11(3-4):265-70 [7389984.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):311-6 [9063752.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):791-7 [9843173.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):721-3 [10501418.001]
  • [Cites] Thromb Haemost. 1995 Oct;74(4):1120-5 [8560423.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4 [2349221.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):212-8 [15641049.001]
  • [Cites] Thromb Haemost. 1992 May 4;67(5):499-502 [1519207.001]
  • [Cites] Clin Exp Immunol. 1985 Dec;62(3):738-45 [4085154.001]
  • [Cites] J Immunol. 1996 Oct 15;157(8):3744-51 [8871678.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]
  • (PMID = 16724168.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


93. Deeb A, Hamdoun S, Dababo K: Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis. Iran J Immunol; 2009 Sep;6(3):154-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Antiphospholipid antibodies (aPL) are a heterogeneous family of antibodies associated with thrombosis and other complications.
  • OBJECTIVE: To study the prevalence of aPL in patients with thrombosis at Aleppo University Hospitals, Syria.
  • RESULTS: Thirty-four out of 157 (21.7%) patients with thrombosis had some type of aPL. aPL was also found in four healthy subjects (4/63=6.3%).
  • Eighteen patients (11.5%) were positive for LA, 20 (12.7%) for aCL antibodies and 4 (2.6%) were positive for more than one aPL.
  • Patients without risk factors for thrombosis and having positive aPL were 23/34 (67.7%).
  • Fourteen out of 78 (17.9%) patients with arterial thrombosis, and 20/79 (25.3%) with venous thrombosis were positive for at least one aPL.
  • CONCLUSION: Our study showed a significant prevalence of aPL in patients with thrombosis.
  • It seems that aPL is a risk factor for venous and arterial thrombosis, especially in patients with no conventional risk factors.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Seroepidemiologic Studies. Syria / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801789.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Lupus Coagulation Inhibitor
  •  go-up   go-down


94. Brochet C, Morin N, Coudert M, Vauthier-Brouzes D, Costedoat-Chalumeau N, Bernard M: Impact of antiphospholipid biology in maternal Down syndrome screening. Prenat Diagn; 2009 May;29(5):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Women with antiphospholipid (aPL) biology present obstetric complications.
  • Because AFP is involved in the calculation of the risk of trisomy 21 (T21), we studied the effect of AFP variations in the presence of aPL during T21 screening.
  • METHODS: The study group (aPL group) was comprised of 64 pregnancies in women with aPL antibodies.
  • RESULTS: AFP values, converted in logarithm of multiples of the median (MoM), were significantly higher in the aPL group (0.03 vs 0.10; p = 0.018).
  • After a matricial transformation of AFP MoM and hCG MoM in the aPL group, new T21 risks presented a median of one in 1665 versus one in 2574 (p < 0.0001 with a rank-sign test).
  • CONCLUSION: Our results highlight the fact that in the presence of aPL antibodies, the calculated risk of T21 is underestimated.
  • Therefore, clinicians should interpret the screening borderline results in aPL patients with caution.
  • [MeSH-minor] Adult. Antiphospholipid Syndrome / blood. Antiphospholipid Syndrome / complications. Case-Control Studies. Cohort Studies. Female. Humans. Pregnancy. Pregnancy Complications / blood. Pregnancy Complications / diagnosis. Pregnancy Complications / epidemiology. Pregnancy Outcome. Risk Factors. Sensitivity and Specificity


95. Akoz AG, Dagdas S, Ozet G, Ceran F, Yilmaz M: Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia. Hematology; 2007 Oct;12(5):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia.
  • Extramedullary involvement in the absence of bone marrow disease is rare in patients with acute promyelocytic leukemia (APL).
  • We report two patients with APL who had central nervous system (CNS) relapse without evidence of cytologic and molecular disease of bone marrow after all-trans-retinoic acid (ATRA) treatment.
  • Although increasing number of cases with extramedullary involvement of APL after ATRA including therapy have been reported, further studies with a large series of patients are necessary to determine whether ATRA increases the risk of development of extramedullary involvement of disease in patients with APL.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Humans. Male. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852441.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


96. Obayashi S, Ozaki Y, Sugi T, Kitaori T, Katano K, Suzuki S, Sugiura-Ogasawara M: Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol; 2010 Jun;85(2):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also examined conventional antiphospholipid antibodies (aPL) such as beta2-glycoprotein I-dependent anticardiolipin antibodies (beta2GPI-dependent aCL), lupus anticoagulant with reference to the dilute activated partial thromboplastin time (aPTT) and the diluted Russell's viper venom time (RVVT).
  • [MeSH-minor] Adult. Antibodies, Antiphospholipid / blood. Disease Progression. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Lupus Coagulation Inhibitor / immunology. Predictive Value of Tests. Prognosis. Protein Binding. Risk Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Pregnancy Loss.
  • Genetic Alliance. consumer health - Recurrent spontaneous abortion.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20462639.001).
  • [ISSN] 1872-7603
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / Phosphatidylethanolamine Binding Protein; 0 / Phosphatidylethanolamines; 39382-08-6 / phosphatidylethanolamine
  •  go-up   go-down


97. Tirado CA, Chen W, Valdez F, Karandikar N, Arbini A, Acevedo I, Garcia R, Davila O, Smart RL, Matthews E, Kirk A, Collins RH: Unusual presentation of myeloid sarcoma in a case of acute promyelocytic leukemia with a cryptic PML-RARA rearrangement involving multiple sites including the atrium. Cancer Genet Cytogenet; 2010 Jul 1;200(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of myeloid sarcoma in a case of acute promyelocytic leukemia with a cryptic PML-RARA rearrangement involving multiple sites including the atrium.
  • Myeloid sarcoma may develop de novo, concurrently with acute myeloid leukemia (AML), or at relapse.
  • Reported here is the case of a 30-year-old man, initially diagnosed with acute promyelocytic leukemia (APL) in bone marrow, who presented later with myeloid sarcoma at multiple anatomical sites (left scapula, thoracic vertebra, right atrium, and supraclavicular mass) in multiple relapses.
  • Fluorescence in situ hybridization studies confirmed a cryptic PML-RARA fusion on the short arm of chromosome 7, as well as a second fusion on one copy of chromosome 15.
  • With the fourth and latest relapse, molecular cytogenetic studies performed on interphase nuclei of the myeloid sarcoma specimen (a supraclavicular mass) showed evidence of six related abnormal clones with a PML-RARA fusion, suggesting clonal evolution.
  • This represents a rare case of APL with a cryptic PML-RARA rearrangement presenting as myeloid sarcoma at multiple relapses and involving multiple anatomical sites, including cardiac atrium.
  • [MeSH-major] Gene Rearrangement. Heart Neoplasms / genetics. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Sarcoma, Myeloid / genetics
  • [MeSH-minor] Adult. Flow Cytometry. Heart Atria / pathology. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20513534.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


98. Rees JD, Lança S, Marques PV, Gómez-Puerta JA, Moco R, Oliveri C, Khamashta MA, Hughes GR, D'Cruz DP: Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis; 2006 Jan;65(1):109-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Outpatients and inpatients were both included and were assessed for features of the APS and presence of aPL.
  • RESULTS: Of 144 patients with PSV, 25 had positive aCL or LA on at least one occasion, representing a point prevalence of 17%.
  • Twelve had only positive aPL.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / blood. Female. Humans. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Prevalence. Retrospective Studies

  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2000 May;39(5):565-7 [10852993.001]
  • [Cites] Br J Rheumatol. 1998 Feb;37(2):208-10 [9569078.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]
  • [Cites] Ann Rheum Dis. 1984 Oct;43(5):746-8 [6497467.001]
  • [Cites] Clin Immunol Immunopathol. 1986 Oct;41(1):8-15 [3742889.001]
  • [Cites] Br J Rheumatol. 1998 Nov;37(11):1251-3 [9851284.001]
  • [Cites] Rheumatology (Oxford). 1999 May;38(5):478-9 [10371294.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]
  • [Cites] J Rheumatol. 1989 Jun;16(6):716-7 [2778755.001]
  • [Cites] Arch Intern Med. 1986 Nov;146(11):2153-6 [3535715.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1065-7 [2390119.001]
  • [Cites] Arthritis Rheum. 1994 Feb;37(2):187-92 [8129773.001]
  • [Cites] Lupus. 1994 Dec;3(6):523-4 [7704011.001]
  • [Cites] Am J Nephrol. 1995;15(2):157-60 [7733154.001]
  • [Cites] Semin Arthritis Rheum. 1995 Feb;24(4):273-81 [7740307.001]
  • [Cites] Thromb Haemost. 1995 Oct;74(4):1185-90 [8560433.001]
  • [Cites] Am J Med. 1996 Dec;101(6):576-83 [9003103.001]
  • [Cites] Br J Rheumatol. 1997 Nov;36(11):1210-2 [9402867.001]
  • [Cites] Lupus. 1998;7(1):51-2 [9493150.001]
  • [Cites] Lupus. 2000;9(9):717-20 [11199929.001]
  • (PMID = 16344494.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Lupus Coagulation Inhibitor
  • [Other-IDs] NLM/ PMC1797969
  •  go-up   go-down


99. Sidelmann JJ, Sjøland JA, Gram J, Bertelsen V, Mourits-Andersen T, Münster H, Münster AM, Jespersen J: Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest; 2007;67(3):270-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Lupus anticoagulant (LA) and antiphospholipid antibodies (aPL) are suggested as risk factors for development of deep vein thrombosis (DVT) among patients without systemic lupus erythematosus (SLE).
  • In this study the associations between aPL, LA and inflammation were investigated in 170 consecutive patients without SLE, but with a tentative diagnosis of DVT.
  • CONCLUSIONS: The present study supports a strong association between inflammatory reactions and development of LA in patients with suspected DVT, whereas no significant association was demonstrated between LA or aPL and DVT.
  • [MeSH-minor] Adult. Aged. Antibodies, Anticardiolipin / blood. Antibodies, Anticardiolipin / immunology. Biomarkers. Blood Coagulation Tests. C-Reactive Protein / analysis. C-Reactive Protein / immunology. Female. Humans. Male. Middle Aged. Phlebography. Risk Factors

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454841.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Biomarkers; 0 / Lupus Coagulation Inhibitor; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


100. Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE: Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis; 2008 Mar;67(3):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in systemic lupus erythematosus (SLE) patients with and without antiphospholipid antibodies (aPL).
  • METHODS: Sera and clinical data were obtained from the Hospital for Special Surgery Autoimmune Disease Registry for 78 aPL-positive and 91 aPL-negative SLE patients without heparin-induced thrombocytopenia (HIT).
  • RESULTS: Positive anti-HPF4 was seen in 9% of aPL-positive SLE patients, 4% of aPL-negative SLE patients and 1% of controls (p = 0.026, aPL-positive SLE vs controls).
  • CONCLUSIONS: Anti-HPF4 is detectable in SLE patients with and without aPL in the absence of HIT, and is most prevalent in aPL-positive SLE patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Antiphospholipid / blood. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Antiphospholipid Syndrome.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644539.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL067211; United States / NIAMS NIH HHS / AR / K23 AR050607-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 37270-94-3 / Platelet Factor 4; 9005-49-6 / Heparin
  •  go-up   go-down






Advertisement